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The CDC estimates that approximately 20.9% of U.S. adults currently smoke. 
Moreover, cigarette smoking continues to be the leading preventable cause of death 
and disability in the United States making it is a significant public health problem.  
Although 70% of smokers express a desire to quit, relapse is quite common, with 
rates as high as 60-90% depending on the method of quitting used.  Moreover, many 
smokers who attempt to quit, lapse within a few days, and many of these individuals 
ultimately resume smoking and are not able to recover to achieve abstinence.  The 
initial experience of smoking cessation is stressful and is associated with a number of 
unpleasant withdrawal symptoms.  Therefore, one particular hypothesis suggests that 
how an individual reacts to and tolerates these uncomfortable feelings may be a key 
contributing factor of relapse.  This threshold for tolerating physical and 
psychological stress is known as distress tolerance.  While early evidence has 
suggested that distress tolerance is associated with duration of quit attempts, to date, 
no study has examined the effects of distress tolerance across physical, psychological 
and biological domains on a number of other relapse predictors (e.g. negative affect, 
  
anxiety sensitivity and withdrawal symptoms) in determining smoking outcome.  
Therefore, the following study looked at the role of these variables in predicting 
smoking outcome in a group of 58 adult smokers who entered a smoking cessation 
treatment study.   As hypothesized, both measures of physical distress tolerance and 
one measure of psychological distress tolerance significantly predicted time to 
smoking lapse above and beyond other smoking related variables.  There was no 
relationship between smoking abstinence and self-report and biological measures of 
distress tolerance.  There were also no significant findings with respect to any affect 
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Chapter 1: Theoretical Rationale  
Public Health Significance of Smoking 
Cigarette smoking is highly prevalent both in the United States and throughout the 
world.  In the United States, approximately 44.5 million adults (20.9%) currently smoke, 
with over 81% endorsing daily use and 19% reporting less consistent use (CDC, 2005b).  
In general, it is estimated that about 25% of individuals living in developed nations are 
habitual smokers, with daily consumption ranging from around 14 cigarettes per day in 
low income countries to 22 cigarettes per day in high income countries (Zaher et al., 
2004).  The DSM-IV defines nicotine dependence as a maladaptive pattern of substance 
use resulting in clinically significant impairment or distress as evidenced by three or 
more criterion symptoms of dependence.  These symptoms include: tolerance, 
withdrawal, nicotine being consumed in larger amounts than intended, persistent desire to 
cut down or control nicotine use, a great deal of time spent in activities to obtain, use, or 
recover from the effects of nicotine, reduction in social, occupational, or recreational 
activities due to nicotine use, and continued use of nicotine despite having knowledge of 
specific psychological or physical harm caused by or exacerbated by the use nicotine 
(American Psychiatric Association, 1994).  It is assumed that within a few years of daily 
smoking, most smokers will begin to develop dependence and notice withdrawal 
symptoms upon smoking cessation (UDHHS, 1994).  For example, approximately 50% 
of current smokers in their twenties meet criteria for nicotine dependence (Breslau, 
Kilbey, & Andreski, 1994).  The National Comorbidity Survey Replication (NCS-R) 




10.5% of females and 11.6% of males meeting criteria (Kessler, Chiu, Demler, 
Merikangas, & Walters, 2005).  Although this rate is substantially lower than that 
published in the original NCS (24%; Breslau, Johnson, Hiripi, & Kessler, 2001) and the 
Epidemiological Catchment Area Study (ECA; 36.6%; Robins, Helzer, Przybeck, 1986), 
overall prevalence rates of smoking have declined over the past two decades due to 
increased public health efforts (CDC, 2005b).  In addition, these surveys used older 
versions of the DSM which were thought to be over inclusive (Hughes, Gust, & 
Pechacek, 1987), and employed less stringent criteria (i.e. three or more lifetime criteria 
versus two or more in the 12-month period).  
 Cigarette smoking is the leading preventable cause of death in the United States 
(USDHHS, 1990).  It has been estimated that smoking causes an average of 440,000 
deaths, which accounts for about one out of five deaths per year (CDC, 2003).  In fact, 
more deaths are caused each year from smoking than from human immunodeficiency 
virus (HIV), illegal drug use, alcohol use, motor vehicle injuries, suicides, and murders 
combined (CDC, 2002; McGinnis & Foege, 1993).  Smoking is associated with many 
diseases such as lung, oral, and a host of other cancers, cardiovascular disease, chronic 
obstructive pulmonary disease, peptic ulcers, gastrointestinal disorders, maternal/fetal 
complications and a variety of other serious health complications (Bartecchi, MacKenzie, 
& Schrier, 1994; Peto, Lopez, Boreham, Thun, & Heath, 1992).  It is estimated that about 
45% of all smokers will die of a tobacco-related disorder and smokers tend to die about 
14 years earlier than nonsmokers (Peto, Lopez, Boreham, Thun, & Heath, 1992; CDC, 
2002).  In addition to the direct impact of smoking, secondhand smoke causes about 




and almost 1,000 infant deaths can be attributed to smoking during pregnancy (CDC, 
2005a).  In addition to the human cost, it is estimated that $92 billion (1997-2001) in 
productivity is lost due to deaths from smoking, with the economic costs of smoking 
totaling more than $167 billion, including an additional $75.5 billion in smoking-related 
medical expenditures (CDC, 2005a).  These sobering statistics offer a clear picture of 
huge public health impact that cigarette smoking has on our society.  
Smoking Cessation Treatments 
Given the issues related to the morbidity and mortality of chronic cigarette 
smoking, there has been a huge public health campaign aimed at reducing the prevalence 
of smoking in the United States.  While the ultimate public health goal may be to develop 
primary prevention strategies aimed at curbing the initiation of smoking behavior, 
smoking cessation treatments can aid those individuals who already smoke and are 
motivated to quit.  Although approximately 70% of current smokers maintain that they 
would like to quit smoking, relapse rates are high, with the one-year quit ratio in the 
general smoking population at less than 1% (Fiore et al., 1989).  The majority of 
individuals who attempt to quit smoking (about 90%), do so on their own without the aid 
of any formalized treatment (USDHHS, 1990).  Within this group of self-quitters, 33% 
remain abstinent after two days and only about 5% are still smoke free after one year 
(CDC, 2002b).  In particular, one study followed a group of 235 self-quitters and found 
that over 1/3 of smokers relapsed within 24 hours and another 1/3 within 48 hours 
(Garvey, Bliss, Hitchcock, & Heingold, 1992).  In fact, by six months only 3% of the 
sample had remained abstinent.  However, it is important to note that most smokers make 




1990).  Those individuals who seek out formal treatments fare slightly better, however 
relapse rates are still as high as 70-85% (Fiore, Bailey, & Cohen, 2000).  However, 
compared to relapse rates following a self-quit attempt, one can conclude that smoking 
cessation treatments do contribute to improved smoking outcomes for many individuals.  
While there are a number of different treatment modalities currently available, the two 
with the most scientific evidence are pharmacotherapy and behavioral treatments. 
Pharmacotherapy  
Guidelines for the treatment of tobacco use and dependence offered by the 
Department of Health and Human Services cite the effectiveness of pharmacotherapy in 
increasing smoking abstinence, with the recommendation that these treatments be used in 
all individuals who are trying to quit smoking and for whom it is not contraindicated for 
physical reasons (Fiore et al., 2001).  In particular, the guidelines highlight four nicotine 
replacement therapies (NRT; gum, inhaler, nasal spray, and patch) and one antidepressant 
(Bupropion SR) as being safe and effective methods for quitting smoking. 
Nicotine Replacement Therapy. Nicotine replacement therapies work by 
providing the smoker with an alternative safer form of nicotine that directly relives some 
of the symptoms of withdrawal and craving that commonly occur during abstinence from 
smoking (Jaffe, 1985).  Depending upon the type of product used, these treatment can 
provide a continuous, stable dose of nicotine over an extended period of time (i.e. patch) 
or a more rapid onset and shorter duration to help curb symptoms and cravings as they 
occur (i.e. spray, gum, inhaler).  All forms of NRTs appear to be equally as effective 
(Hajek, West, Foulds, Nilsson, Burrows, & Meadow, 1999), though compliance was 




host of clinical trials support the efficacy of NRTs in helping increase rates of smoking 
cessation.  For example, a meta-analysis by Fiore, Smith, Jorenby & Baker (1994) 
examined the efficacy of the nicotine patch in increasing smoking abstinence.  They 
reviewed 17 double-blind placebo-controlled studies (n=5098) and found that six-month 
abstinence rates for smokers on the patch was 22% compared to 9% for placebo.  
Similarly, Silagy, Mant, Fowler, and Lodge (1994) conducted a meta-analysis of the 
effects of NRTs broadly on the smoking abstinence rates across 53 randomized controlled 
trials (n = 17,703).  They found that the use of an NRT increased the odds of remaining 
abstinent by almost two-fold (OR = 1.71) compared to control interventions (range of 
1.61 for gum to 3.05 for inhaler).  More recently, Silagy, Lancaster, Stead, Mant, & 
Fowler (2002) conducted a Cochrane Library Systems Review to examine the 
effectiveness of five different types of NRTs (i.e. gum, patch, nasal spray, inhaler, and 
tablets) on smoking abstinence.  They identified one hundred randomized clinical trials 
(48 gum, 30 patch, four nasal spray, four inhaler, and two tablet) and similar to their 
earlier study found that the use of NRTs overall increases the odds of quitting smoking 
by almost two fold (OR = 1.71).  In addition, NRTs have also been shown to be effective 
in light smokers (i.e. 15 or fewer cigarettes per day; Shiffman, 2005), very heavy smokers 
(i.e. 40 or more cigarettes per day; Shiffman, Di Marino, & Pillitteri, 2005), and those 
who have failed previous quit attempts using other pharmacological treatments such as 
different NRTs and Zyban (Shiffman, Dresler, & Rohay, 2004).  Finally, because most 
data on the efficacy of NRTs have been conducted using clinical trials, Alberg and 
colleagues (2005) looked at both the prevalence and effectiveness of NRT use in the 




that 36% of smokers had endorsed using NRTs.  However, interestingly, 30% of those 
individuals who used NRTs had quit smoking compared to 39% of nonusers.  The 
authors hypothesize that users of NRTs may be more severe cases and only turn to this 
method after several unsuccessful quit attempts using other means. 
Bupropion, Bupropion (Zyban) is a selective re-uptake inhibitor of dopamine and 
noradrenalin.  While the exact mechanisms through which Bupropion works to promote 
smoking cessation is unclear, it is believed to be related to the reduced re-uptake of 
dopamine in the mesolimbic system (Ascher et al., 1995), and of noradrenalin in the 
locus coeruleus (Ferry, 1999).  These areas are believed to be stimulated by nicotine and 
associated with symptoms of cravings and withdrawal.  Consistent with this hypothesis, 
Bupropion has been shown to reduce the severity of craving during smoking cessation 
compared to other types of treatments (Hurt et al., 1997; Jorenby et al., 1999; Tashkin et 
al., 2001).  Results from a number of clinical trials support the efficacy of Bupropion for 
smoking cessation.  For example, in the guidelines for smoking treatment provided by 
DHHS, Fiore et al. (2000) reported that at the end of six months approximately 30% of 
smokers who used Bupropion were no longer smoking compared to 18-30% of those 
using nicotine replacement therapy.  In addition, a Cochrane Library Systematic Review 
pooled results from19 clinical trials of Bupropion found that use of the drug more than 
doubled the odds of remaining abstinent from smoking (OR = 2.06; Hughes, Stead, & 
Lancaster, 2003).  Compared to other pharmacotherapies, Bupropion has been shown to 
be more effective.  One study examining the efficacy of Bupropion versus the nicotine 
patch found significantly higher rates of smoking abstinence at both six and 12-month 




patch alone or placebo (Jorenby et al., 1999).  In addition, a recent six-week, randomized 
open label trial comparing Bupropion to Gabapentin found Bupropion to be superior in 
reducing withdrawal symptoms and promoting smoking cessation (White, Crockford, & 
Patten, 2005).  Finally, two studies looked at the efficacy of retreatment using Bupropion 
in smokers who previously failed to respond. They found 6-to-12 month continuous 
abstinence rates of 12% and 9%, respectively for Bupropion compared to 2.0% for 
placebo (Gonzales, Nides, Ferry, 2001), and a 12-month point prevalence abstinence of 
19% for Bupropion and 9% for placebo (Gonzales, Nides, Ferry, 2002).  
The overall findings of pharmacological treatments for smoking are promising in 
helping to reduce relapse and promote smoking abstinence, however relapse rates are still 
high and there is a need for improvement.  While NRTs help smokers alleviate some of 
the unpleasant physical and psychological symptoms associated with nicotine 
withdrawal, behavior therapy can address the conditioned cues, reinforcers and social 
context associated with smoking and can help the individual make lifestyle changes to 
effectively live smoke free.  In fact, studies have shown that pharmacological treatments 
are most successful when implemented in a context that includes behavioral interventions 
(Fagerstrom, 1988; Fiore, Bailey, Cohen, Dorfman,, Goldstein, & Gritz, 2000). 
Standard Behavioral Treatment 
 Behavioral techniques for smoking cessation emerged in the 1960s and continue 
to be an effective tool for smoking cessation (Fiore et al., 2000).  In particular, cognitive 
social learning theory (Bandura, 1997) provides a good behavioral framework for 
understanding these intervention strategies.  Specifically, this model conceptualizes 




such as classical and operant conditioning, modeling, behavioral self-control, self-
efficacy, and outcome expectancies (Brown & Emmons, 1991).  While the exact 
components of behavioral smoking treatments vary, they typically address three distinct 
stages of treatment: preparation for quitting, quitting, and maintenance or relapse 
prevention.  In line with this, Fiore and colleagues (2000) cite practical skills counseling 
(i.e. problem solving/skills training/stress management/relapse prevention), social support 
both in and out of the treatment setting, and aversive smoking interventions to be 
techniques associated with improved smoking outcomes. 
 In terms of preparing the individual to begin the process of quitting, motivational 
interviewing (MI) is a popular behavioral technique used for the treatment of alcohol use 
and other addictive disorders (Hettema, Steele, & Miller, 2005) that has also been applied 
to smoking cessation (Rollnick, Butler, & Stott, 1997).  Motivational interviewing is a 
direct yet client centered technique which works to enhance intrinsic motivation to 
change through exploring and resolving the individual’s ambivalence (Miller & Rollnick, 
2002).  In particular, Miller and Rollnick (2002) outline four basic principles of MI which 
include; expressing empathy, developing discrepancy, rolling with resistance, and 
supporting self-efficacy.  The main advantage of MI is that it works to motivate 
individuals who may not be entirely ready to give up smoking to begin making changes 
in regards to their thoughts and behaviors that will eventually lead them to quit.  There is 
some evidence to suggest that MI is efficacious in smoking cessation (Butler et al., 1999; 
Colby et al., 1998).  For example, Soria and colleagues (2006) found that a combination 




smokers to quit compared to bupropion and anti-smoking advice (abstinence rates of 18.4 
versus 3.4%, respectively). 
 According to the guidelines constructed by Fiore et al (2000), practical counseling 
is an important and effective component of any behavioral smoking treatment.  They 
outline a number of examples of practical counseling that are utilized to some degree in 
most behavioral treatments.  The first of these includes skills related to identifying high 
risk situations that may contribute to relapse.  This can include any situational variable 
(e.g. being around other smokers, exposure to alcohol), internal state (e.g. stress, negative 
affect, cravings), or activity (e.g. being in a rush) that can precipitate an early relapse.  In 
addition, practical counseling can incorporate the development and mastery of coping 
skills used to help deal with these potential high risk situations.  This can include 
elements such as learning to anticipate and avoid high-risk situations, developing 
strategies and making changes to deal with stress, negative affect or any other unpleasant 
mood state that could contribute to relapse, and learning new activities and habits that 
help suppress cravings or urges.  Finally, it is important to engage in some form of 
relapse prevention.  Specifically, this includes basic information about what to expect 
during the smoking withdrawal process, the addictive nature of smoking, and the danger 
of a smoking lapse progressing into relapse (for reviews on practical counseling 
techniques see Brown 2003; Curry & McBride, 1994). 
Social support has been identified as a key factor in promoting smoking 
abstinence; therefore it recommended that behavioral treatment incorporate some type of 
social support element (Fiore et al. 2001).  The focus of social support can vary 




and encouragement by the therapist and group members (if applicable) and acquiring 
skills to help the individual seek social support outside of treatment.  One example of this 
would be behavioral contracting where the patient enlists in the aid of a friend or loved 
for help in abstaining from cigarettes and maintaining a smoke free lifestyle.  Studies 
have found that social support when used in conjunction with other behavioral techniques 
significantly improves the chances of quitting smoking (Etringer, Gregory, & Lando, 
1984; Hamilton & Bornstein, 1979; Lichtenstein, E., Glasgow, R. E., & Abrams, D. B., 
1986).  For example, West, Edwards, and Hajek (1998) found that when smokers 
attending a smoking clinic were paired with a “buddy” (another smoker attempting to 
quit), they reported significantly higher four week abstinence rates compared to those 
smokers in the solo condition (27% vs. 12%, respectively).  In addition, a longitudinal 
study examined three types of social support: support from a partner directly related to 
quitting, perceptions of the availability of general support resources, and the presence of 
smokers in the subject’s social network (Mermelstein, Cohen, Lichtenstein, Baer, & 
Kamarck, 1986).  They found that all three elements of social support were important, but 
at different points in the cessation process.  Specifically, high levels of partner support 
and perceived availability of support were associated with smoking cessation and short-
term abstinence (i.e. up to 3 months) while smokers in the subject’s social network was 
associated with maintenance and long-term abstinence  
 Finally, aversive smoking techniques pair smoking with negative sensations to 
reduce the pleasure associated with smoking and extinguish the behavior.  Rapid smoking 
is the most commonly employed aversive technique and typically involves having the 




continue.  While rapid smoking, the individual is directed to focus on the unpleasant 
sensations produced.  Other aversive techniques include rapid puffing, smoke holding, 
excessive smoking, self-paced smoking, covert sensitization and use of electric shocks or 
bitter pills (Hajek & Stead, 2000).  Results from a Cochrane Database System included 
twenty-five trials using either rapid smoking or some other type of aversion method and 
found an almost two-fold (OR = 1.98) increase in smoking cessation compared to control 
groups (Hajeck & Stead, 2000).  However, the authors note a number of methodological 
limitations across these studies that may have resulted in spurious results, so more work 
needs to be done to determine the effectiveness of this technique.  Therefore, they are 
recommended in situations where more desirable treatments may have failed (Fiore et al. 
2000). 
 Overall, behavioral theories offer a number of different techniques aimed at 
quitting smoking and maintaining a smoke free lifestyle.  Although pharmacological 
agents work to help alleviate some of the unpleasant withdrawal symptoms associated 
with smoking, behavioral techniques offer the coping skills, support and psychoeducation 
that are necessary in reducing relapse rates. 
Overview of Smoking Relapse 
Theory of Smoking Relapse 
 The most well-known and utilized theory of relapse prevention is the cognitive-
behavioral model proposed by Marlatt and Gordon (1980, 1985).  According to this 
model, relapse (i.e. a setback in an individual’s attempt to change or modify a particular 
behavior) occurs as the result of exposure to a high-risk situation.  Specifically, if an 




coping response to deal with the situation, or chooses not to implement it due to factors 
such as motivation or anxiety, then there is an increased risk of a smoking lapse (i.e. a 
single slip or mistake).  In addition, this increased probability of a lapse is mediated by 
other factors such as the individual’s positive expectancies regarding the outcome of 
smoking and decreased self-efficacy regarding their perceived lack of ability to cope with 
the situation.  However, according to this model, a smoking lapse does not necessarily 
have to result in a full-blown smoking relapse.  In cases where the individual possess 
effective skills to cope with the situation, they can prevent a lapse from progressing into 
relapse and can proceed with smoking abstinence.  However, following a lapse, many 
individuals may experience what is known as the abstinence violation effect (AVE), a 
phenomenon which basically refers to the loss of perceived control that is experienced 
following a lapse in smoking (Curry, Marlatt, & Gordon, 1987).  The AVE operates on 
three distinct levels to increase the likelihood of full blown relapse.  First, the AVE 
causes the smoker to feel negative emotions such as shame, guilt and blame which can 
lead the individual to want to smoke to alleviate some of these feelings.  Secondly, the 
AVE can lead to cognitive dissonance due to the inconsistency between the individual’s 
desire to be a nonsmoker and their reality of just having smoked a cigarette.  Finally, the 
AVE can lead the individual to make stable, internal, and global attributions about their 
failure to remain abstinent which can contribute to feelings of low self-efficacy regarding 
their ability to remain abstinent.  All of these consequences associated with the AVE can 
operate independently or in conjunction with one another to increase the probability that 
once these individuals smoke one cigarette they will abandon their quit attempt and 




both positive and negative reinforcement which further increases the probability of 
continuing to smoke.  
 There have been a number of studies conducted evaluating this relapse prevention 
model which focus on either cognitive behavioral treatments designed to address relapse 
prevention strategies or the AVE (e.g. Baer & Lichtenstein, 1988; Brandon et al., 2000; 
Shiffman, Hitchcox 196 and 1997).  For example, Bliss and colleagues (1989) conducted 
a prospective study that observed self-quitters over the course of one-month following 
smoking cessation to determine what variables contributed to a relapse crisis.  In this 
particular study a relapse crisis was defined as either a smoking lapse or a situation in 
which the individual experienced the strongest temptation to smoke.  They found that 
variables such as the presence of other smokers, withdrawal symptoms and negative 
affect were common precipitants of the relapse crisis.  However, consistent with Marlatt 
and Gordon (1985), smoking abstinence was strongly related to the number of cognitive-
behavioral coping strategies used during the situation.  In addition, Curry, Marlatt, and 
Gordon (1987) looked at the validity of the AVE as defined by internal, stable and global 
causal attributions for cigarette smoking following a period of abstinence.  Following 
completion of a smoking cessation treatment, those individuals who relapsed were asked 
to provide retrospective causal attributions for initial smoking lapses.  They found that 
those smokers who relapsed following a slip reported significantly more AVEs than those 
who regained abstinence following their lapse.  In addition, AVE was the most robust 
predictor of subsequent smoking following an initial smoking lapse.  However, it is 
important to note that not all studies have found support for Marlatt and Gordon’s relapse 




review by Irvin and colleagues (1999) looked at 26 different studies that employed some 
type of relapse prevention treatment consistent with the model and found that while 
relapse prevention was reliable and effective, it was more successful in treating alcohol 
and illicit substance use than smoking.  However, despite these inconsistencies in the 
literature, Marlatt and Gordon’s model (1980) continues to be the most commonly 
ascribed theory of relapse. 
Importance of Early Smoking Lapse and Relapse 
Although Marlatt and Gordon’s (1985) model of relapse highlights the importance 
of situational factors leading to relapse during the initial three to six months following 
cessation, there is evidence suggesting that the majority of individuals who lapse do so 
within the first couple of weeks of quitting.  For example, Hughes, Keely, and Naud 
(2004) conducted a review of seven studies including either self-quitters or a no-
treatment control group and found that the majority of smokers relapsed within 8 days of 
quitting.  In addition, Gulliver, Hughes, Solomon, and Dey (1995) followed a group of 
630 smokers attempting to self-quit and found that over 50% of the sample had endorsed 
smoking  more than one cigarette by day 2 with an additional 21% lapsing within two 
weeks. This risk of early smoking lapse is evident in both self-quitters and those who 
receive formal smoking cessation treatment (Cook, Gerkovich, O’Connell, & Potocky, 
1995; Doherty, Kinnunen, Militello, & Gravey, 1995; Shiffman et al., 2000; Shiffman, 
Hickcox, Paty, Gnys, Richards, & Kassel, 1997; Spanier, Shiffman, Maurer, Renyolds, & 
Quick, 1996; Westman, Behm, Simel, & Rose, 1997)  For example, Zhu and colleagues 
(1996) conducted a large scale study where smokers where assigned to one of three 




59% of subjects in self-help, 54% in single and 49% in multiple contact groups smoked 
within the first week.  
  Although pharmacological treatments are designed to minimize withdrawal 
symptoms thus theoretically reducing early relapse, the data still evidence high rates of 
early relapse.  For example, Shiffman and colleagues (2006) looked at the effects of a 
high-dose nicotine patch versus placebo in a group of adult smokers.  They found that the 
patch was effective in providing initial abstinence (i.e. 24 hours without smoking), but 
amongst those smokers who were able to achieve initial abstinence, 67.2% lapsed.  In 
fact, the median duration of abstinence achieved in the patch condition was six days 
compared to two days for the placebo.  These findings are consistent with other studies 
that have found even with the NRT, most lapses occurred within the first week (Doherty, 
Kinnunen, Militello, & Garvey, 1995; Shiffman et al., 2000 and 1997).  Although another 
set of studies fared slightly better, 43-50% of participants receiving the nicotine spray or 
inhaler endorsed smoking within the first week, which is still considerably high 
(Schneider et al., 1995; Schneider, Olmstead, Nilsson, Mody, Franzon, & Doan, 1996). 
Therefore, the overall conclusion gleaned from these results is that the initial first weeks 
of smoking cessation tend to be the most vulnerable to smoking lapses. 
There is ample evidence to suggest that the majority of individuals who lapse 
within the first couple weeks of smoking cessation will ultimately progress to full relapse.  
It has been estimated that between 80% to almost 100% of individuals who experience a 
smoking lapse return to some form of regular smoking (Brandon et al., 1990; Cook, 
Gerkovich, O'Connell, & Potocky, 1995; Brown, Herman, Ramsey, & Stout, 1998; 




Rosner, 1992; Kenford et al., 1994;  Shiffman, Hickcox, Paty, Gnys, Richards, & Kassel, 
1997; Norregaard, Tonnesen, & Petersen , 1993; Smith, Jorenby, Fiore, Anderson, 
Mielke, & Beach, 2001).  Chornock, Stitzer, Gross, & Leischow (1992) looked 
prospectively at the effects of smoking exposure following a brief period of abstinence.  
Sixty-seven smokers who had completed three days of smoking abstinence were 
randomly assigned to either smoke five of their own cigarettes or remain abstinent during 
a discrete period of time on the fourth day.  Afterwards, all subjects were informed that 
they were free to resume smoking.  They found that subjects from the programmed lapse 
condition were quicker to return to smoking compared to those in the abstinence 
condition suggesting that exposure to cigarettes following smoking cessation increases 
the probability of subsequent smoking.  A similar result was found in a more recent study 
employing similar methodology but controlling for nicotine exposure (Juliano, Donny, 
Houtsmuller, & Stitzer, 2006).  Therefore, these studies suggest that initial smoking 
lapses can have a negative effect on subsequent smoking outcomes.  In addition, this 
effect is not entirely due to pharmacological effects of nicotine and other internal and 
situational factors play a role.      
 Taken together, the overall conclusion is that regardless of the treatment modality 
employed, smoking lapses within the first several days of abstinence are a common 
phenomenon.  Moreover, smokers who tend to lapse early are at a higher risk for 
subsequent relapse.  It is plausible that there are unique individual factors that 
differentiate this group of high-risk smokers from those who are able to successfully 




next section will review some of the predictors found to contribute to early smoking lapse 
and relapse.  
Predictors of Early Smoking Lapse/Relapse  
Withdrawal Symptoms 
Smoking cessation is associated with a number of negative withdrawal symptoms 
such as anxiety, irritability, difficulty concentrating, hunger, impatience, restlessness, and 
cravings for tobacco (Hughes, 1992; Hughes, Gust, Skoog, Keenan, & Fenwick, 1991; 
Hughes & Hatsukami, 1986).  While the majority of these symptoms tend to remit within 
a month following cessation, others such as hunger and cravings tend to persist for up to 
six months or longer (Hughes, Gust, Skoog, Keenan, & Femwick, 1991).  
Pharmacological theories of smoking relapse posit that withdrawal symptoms are a 
hallmark of nicotine dependence and play an instrumental role in smoking maintenance 
and relapse behavior (Benowitz, 1983; Benowitz, 1992; Gilman, Goodman, Rall, & 
Murad, 1985; Henningfield & Goldberg, 1988; Schachter, 1978; Shiffman, 1991; 
Stolerman & Shoaib, 1991).  Specifically, they hypothesize that withdrawal symptoms 
are the direct result of neural adaptations to chronic levels of nicotine in the body that 
once removed cause a disruption in the adapted symptoms.  As a result, the individual 
experiences a cluster of aversive symptoms that are directly related to the inability of 
some smokers to successfully quit.  In particular, it is hypothesized that these symptoms 
contribute to smoking due to the individual’s desire to avoid and/or reverse smoking 
withdrawal symptoms. 
While smokers will often attribute their cessation failures to aversive withdrawal 




empirical studies specifically examining the role of these symptoms in smoking relapse 
have been equivocal.  For example, Patten and Martin (1996) conducted a review of 15 
prospective studies and found that neither individual withdrawal symptoms or the total 
frequency and severity of symptoms served as a consistent predictor of smoking cessation 
or relapse.  In fact, only six of the studies reviewed evidenced a significant association 
between withdrawal symptoms and either early-or long-term abstinence (Covey, 
Glassman, & Stetner, 1990; Gritz, Carr, & Marcus, 1991; Gunn, 1986; Persico, 1992; 
Robinson, Pettice, & Smith, 1992; West, Hajek, & Belcher, 1989), while the other nine 
did not (Hall, Hall; Hughes, Hughes et al,  Hughes and Hatsukami, Kenford, Fiore, 
Jorenby, Smith, Wetter, & Baker, 1994;  Norregaard, Stitzer & Gross, Swan and Denk).  
In studies where an association was found it tended to be related to short-term as opposed 
to long-term outcomes.  However, this is not entirely surprising since it is consistent with 
the finding that the majority of withdrawal symptoms endure for up to a month.  
Therefore, it is plausible to assume that this initial period would be the highest risk for 
withdrawal related relapse.  Patten and Martin (1996) note that a number of important 
methodological inconsistencies across studies may help explain these equivocal findings.  
For example, measurement issues relating to the construct validity of the symptom 
inventories, reliance on total severity scores as opposed to individual symptoms, and 
variability in duration between assessment periods may all contribute to the inconsistent 
results across studies.  Another important limitation involves sampling.  With the 
exception of Hughes (1992), all the other studies cited used individuals who were seeking 
smoking treatment interventions.  However, the majority of smokers who do attempt to 




who enter treatment programs are distinct from those who self-quit (Fiore et al., 1990; 
Lichtenstein & Hollis, 1992), therefore generalizability of these results across the 
majority of smokers is limited.  
Piasecki and colleagues (1998) noted an important limitation in previous 
withdrawal symptom research was the lack of attention to individual variability and the 
assumption that an aggregate pattern of withdrawal symptoms is applicable to any given 
smoker.  In a series of studies they noted dramatic heterogeneity in individual symptom 
profiles and found that mean symptom elevation and the trajectory of withdrawal 
symptoms were significantly associated with smoking relapse in both self-quitters and 
those using the nicotine patch (Piasecki 1998; 2000).  In particular, individuals displaying 
atypical withdrawal profiles characterized by late peaks and unremitting symptoms were 
more likely to relapse.  The authors noted that perhaps smokers who initially remain 
abstinent but then suffer from increasing withdrawal symptoms may resume smoking as a 
way to decrease their symptoms.  In a later study using more advanced statistical models, 
Piasecki et al (2003a) examined reports of smoking withdrawal in 893 smokers and found 
that those smokers who lapsed evidenced a more aversive symptoms pattern and tended 
to have higher than expected withdrawal symptoms on the day they lapsed.  In addition, 
they found a high degree of variability in terms of the severity, trajectory and variability 
of withdrawal symptoms, and these dimensions were predictive of both smoking lapse 
and relapse (Piasecki et al 2003b).   
 The overall conclusion of the literature on withdrawal symptoms and relapse 
remains unclear.  While anecdotally many smokers report withdrawal symptoms 




methodological issues obscure the findings.  In addition, Piasecki and colleagues note the 
dramatic heterogeneity between individual withdrawal symptoms and trajectories, and 
stress the limitations of using aggregate measures of withdrawal symptoms.  In particular, 
they found that those smokers who displayed withdrawal profiles characterized by late 
peaks and unremitting symptoms were more likely to relapse.  In addition, as will be 
discussed in the next section, recent work has focused on the role of affective withdrawal 
symptoms on smoking relapse.  Therefore, there seems to be some sort of relationship 
between withdrawal symptoms and relapse however the mechanisms underlying this 
association need to be further elucidated.  
Negative Affect-specific Withdrawal Symptoms 
As discussed above, smoking withdrawal is associated with a number of 
unpleasant symptoms including negative affective states (i.e. anxiety, irritability, 
frustration, dysphoria; American Psychiatric Association, 1994).  Recent work has 
suggested that these affective withdrawal symptoms are critical to understanding the 
relationship between withdrawal symptoms and subsequent relapse, especially during the 
first couple weeks of abstinence when withdrawal symptoms are at their peak.  For 
example, Piasecki, Kenford, Smith, Fiore, and Baker (1997) found that negative affect 
was a better predictor of relapse than physical dependence.  Specifically, they found that 
measures of physical dependence did not contribute incremental validity in predicting 
relapse relative to measures of negative affect.  In a later study attempting to replicate 
these findings in a group of self-quitters, Piasecki and colleagues (2000) found that 
variability in negative affect demonstrated a more potent relationship to smoking 




sleep/energy).  These results are consistent with other research that has found that 
affective items contribute most of the reliable variance in withdrawal measures (Welsch 
et al., 1999).  Finally, Kenford and colleagues (2002) found that post-quit negative affect 
(as measured by history of depression and negative affect during the first week of 
quitting) was a more robust predictor of smoking relapse at six month follow-up than 
measures of physical dependence.  Therefore, these studies demonstrate that affective 
withdrawal symptoms play an important role in motivating individuals to return to 
smoking. 
These findings on the role of affective withdrawal symptoms and relapse are 
consistent with the idea that state negative affect is widely believed to play an important 
role in the maintenance and relapse of smoking behavior.  For example, a number of 
people report smoking during situations where they feel stressed or upset (Shiffman, 
1993).  In addition, results from retrospective studies indicate that smokers cite relief 
from negative affect as a core reason for smoking (Brandon & Baker, 1991; Piper et al., 
2004).  However, it is important to note that empirical evidence that nicotine actually 
works to reduce negative affect is equivocal.  In some studies nicotine has been shown to 
reduce negative affect in the context of challenging and/or stressful tasks (Gilbert & 
Spielberger, 1987; Gilbert, Robinson, Chamberlin, & Spielberger, Pomerleau & 
Pomerleau, 1987).  However, other studies that used naturalistic methods of data 
collection to get smoking antecedents in real-time have not found an consistent 
relationship between smoking and affective states (Delfino, Jamner, & Whalen, 2001; 
Shapiro, Jamner, Davydov, & Porsha, 2002; Shiffman et al., 2002; Shiffman, Paty, 




 Although the overall findings examining the purported reliance on cigarettes as a 
means to cope with stress and negative affect states are unclear, it is has been shown that 
those individuals who do tend to smoke more frequently in negative affect situations and 
are less effective in managing these mood states are more likely to relapse (Abrams et al., 
1987; Kamarck & Lichtenstein, 1988; O’Connel & Martin, 1987; O’Connell & Shiffman, 
1988).  Incidentally, several studies do indicate that negative affect (i.e. anxiety, anger, 
depression) serves as an immediate antecedent of smoking relapse (Baer, Kamarck, 
Lichtenstein, & Ransom, 1989; Baer & Lichtenstein, 1988; Bliss, Garvey, Heinold, & 
Hitchcock, 1989; Brandon et al., 1986; Brandon, Tiffany, Obremski, & Baker, 1990; 
Marlatt & Gordon, 1980; Shiffman, 1982).  For example, Shiffman & Waters (2004) 
found increases in negative affect hours before a smoking lapse occurred.  Moreover, it 
has been found that lapses in negative affect situations are more likely to lead to complete 
relapses (O’Connell & Martin, 1987).  However, many of these studies have been 
retrospective in nature, and one study found that individuals attribute stress to smoking 
relapse retrospectively, but not prospectively, highlighting the importance of 
measurement periods (Hall, Harvey, & Wasserman, 1990).  Therefore, a study Shiffman, 
Paty, Gnys, Kassel, & Hickcox (1996) sought to examine factors related to smoking 
temptation and lapse in real-time using palm pilots.  They found that negative affect was 
able to discriminate between lapses, temptations, and random situations, with reported 
levels of negative affect being highest for lapses, followed by temptations, and finally 
random situations.  Furthermore, about 20% of first smoking lapses occurred during 
moments when negative affect was particularly high (i.e. 2.5 SDs above the mean).  In 




retrospectively describe the characteristics of their lapse they tended to exaggerate 
estimates of negative affect during the lapse, suggesting that affective states tend to be 
remembered more by smokers than other factors (Shiffman, Hufford, Hickcox, Paty, 
Gnys, & Kassel, 1997).   
In summary, there appears to be a relationship between negative affect and 
smoking relapse particularly through its role in affect-related withdrawal symptoms.  
However, it is important to note that many individuals experience these symptoms of 
negative affect and are able to resist the urge to smoke and go to achieve abstinence. 
Depression 
In addition to general levels of negative affect, depression has also been found to 
be an important predictor of smoking behavior.  In general, smokers have been shown to 
have higher rates of comorbid depression compared to nonsmokers (Breslau, Kilbey & 
Andreski, 1991; Brown, Lewinsohn, Seely, & Wagner, 1996; Kendler, Neale, MacLean, 
Health, Eaves, & Kessler, 1993) and tend to report higher rates of past major depressive 
episodes (Glassman, Covey, Stetner, & Rivelli, 2001; Ginsburg, Hall, Reus, & Munoz, 
1995; Tsoh et al., 2000).  In addition, individuals with a past history of depression are at 
an increased risk for developing depressive symptoms upon smoking cessation (Borrelli 
et al., 1996; Covey et al., 1997; Niaura, Britt, Borrelli, Shadel, Abrams, & Goldstein, 
1999).  One study found that smoking cessation may lead to a major depressive episode 
in about 15% of individuals with a past history of major depression (Kahler et al., 2002).  
On a related note, smokers with past major depression are more likely to report greater 
increases in negative mood following a quit attempt (Ginsburg et al., 1995).  For 




disorder were more likely to endorse higher levels of anger, confusion and depression 
compared to non-past MDD subjects, and these subjects were more likely to have 
relapsed at six-month follow-up.  However, despite this apparent association between 
past major depression and smoking relapse, treatment studies designed to address this 
proposed vulnerability have demonstrated inconsistent results (Hall, Muñoz, & Reus, 
1994; 1996; 1998).  One study using smokers with a past history of major depression 
compared a standard smoking cessation program to one augmented with cognitive-
behavioral therapy for depression (CBT-D; Brown, Khaler, et al., 1991).   They found 
that both treatments produced similar abstinence rates and that the CBT-D component did 
not significantly increase the odds of quitting.  However, it is important to note that 
secondary analyses, did find that smokers with recurrent past major depression (i.e., two 
or more past major depressive episodes) and heavy smokers who received CBT-D had 
significantly higher abstinence rates than those receiving ST.  Therefore, these results 
suggest that the association between relapse and major depression may not be as clear-cut 
as believed.  In fact, a recent meta-analysis of 15 smoking cessation studies concluded 
that a lifetime history of major depression does not appear to be an independent risk 
factor for cessation failure in smoking cessation treatment (Hitsman et al., 2003).  
Instead, it may be the current levels of depressive symptomotology, rather than a history 
of major depression that is predictive of smoking outcomes.   
There is compelling evidence to suggest that current levels of depressive 
symptoms serve as a more reliable predictor of smoking cessation failure (Anda, 
Williamson, Escobedo, Mast, Giovini, & Remington, 1990; Breslau, Kilbey, & Andreski, 




Hanna, Faden, & Dufour, 1994;  Niaura, Britt, Shadel, Goldstein, Abrams, & Brown, 
2001; Zuckerman, Amaro, Bauchner, & Cabral, 1989).  For example, one study found 
that mean POMS depression scores prior to entering a smoking cessation treatment were 
significantly higher in individuals who were subsequently unable to quit compared to 
those who could quit (Rausch, Nichinson, Lamke, & Matloff, 1990).  In addition, 
Kinnunen and colleagues (1996) found that those smokers with high depressive 
symptoms were less likely to be abstinent at a three-month follow-up compared to those 
smokers with low baseline depressive symptoms.  Finally, a study by Blondal et al. 
(1999) found that independent of treatment condition, high depressive symptom smokers 
showed a decreased likelihood of abstinence at 6-week, 3-month and 6-month follow-
ups.  There are a number of explanations to help account for the poor outcome in 
smoking cessation in individuals with major depression.  For example, these individuals 
begin their quit attempt with higher levels of negative mood, report greater elevations in 
negative mood and overall withdrawal intensity during the first week of quitting, and 
exhibit more anger and depression during the first week of quitting compared to 
individuals without depression (Covey, Glassman, & Stetner, 1990; Ginsberg, Hall, Reus 
& Muñoz, 1995; Hall, Muñoz & Reus, 1994).  
 In conclusion, depression appears to play an important role in both smoking 
behavior and cessation outcome.  However, studies focusing on past history of major 
depressive episodes have been equivocal.  Rather, it appears that baseline levels of 
depressive symptomatology may serve as a more reliable predictor of smoking relapse. 




A number of studies have demonstrated an association between smoking and 
panic disorder.  For example, individuals with panic are more likely to be smokers 
compared to normal controls and individuals with other forms of mental illness 
(Amering, Bankier, Berger, Griengl, Windhaber, & Katschnig, 1999; Lasser, Boyd, 
Woolhandler, Himmelstein, McCormick, & Bor, 2000; Pohl, Yeragani, Balon, Lycaki, & 
McBride, 1992).  In addition, a number of prospective studies have shown that smoking 
can increase the risk in developing panic attacks and panic disorder (Breslau & Klein, 
1999; Isensee, Wittchen, Stein, Hofler, & Lieb, 2003; Johnson, Cohen, Pine, Klein, 
Kasen, & Brook, 2000).  It appears that panic attacks also play an important role in 
smoking relapse.  In particular, one study found that smokers who reported a history of 
nonclinical panic attacks were more likely to endorse shorter quit attempts than those 
without panic attacks (Zvolensky, Lejuez, Khaler, & Brown, 2004).  In addition, these 
smokers also reported more anxiety related withdrawal symptoms (i.e. anxiety, 
restlessness, difficulty concentrating, and irritability) but not other types of symptoms 
during their last quit attempt compared to the nonpanic group.  
In understanding the mechanism involved in this association, increased attention 
has been paid the construct of anxiety sensitivity (AS), a dispositional trait-like cognitive 
vulnerability that has been shown to longitudinally predict panic disorder (Schmidt, 
Lerew, & Jackson, 1997).  Anxiety sensitivity is defined as the fear of anxiety-related 
sensations which are thought to come from the belief that these sensations have harmful 
physical, psychological, or social consequences.  It is typically measured using the 
Anxiety Sensitivity Index (ASI; Reiss, Peterson, Gursky, & McNally, 1986), a brief 16-




negative consequences of anxiety symptoms.  Although the precise role of anxiety 
sensitivity in smoking related behavior is unclear, it is hypothesized that this construct 
may be elevated in a certain subgroup of smokers resulting in distress over the 
pharmacological or nonpharmacological induced interoceptive sensations associated with 
smoking and withdrawal.  Individuals who are high on anxiety sensitivity and also lack 
adaptive coping strategies may turn to smoking as a means of escaping these unpleasant 
interoceptive states (Kassel & Shiffman, 1997; Zvolensly, Schmidt et al., 2003).   
Brown, Kahler, Zvolensky, Lejuez, & Ramsey (2001) looked at the role of 
anxiety sensitivity as measured by the ASI in a group of 60 smokers with a history of 
major depression.  They found that anxiety sensitivity scores were positively correlated 
with smoking as a means to reduce negative affect but not with any other reasons.  These 
results are similar to other studies which found that smokers with elevated levels of 
anxiety sensitivity report smoking as a means to manage their mood (Comeau, Stewart, & 
Loba, 2001; Novak, Burgess, Clark, Zvolensky, & Brown, 2003; Stewart, Karp, Phil, & 
Peterson, 1997).  Other studies have focused on the potential relationship between 
anxiety sensitivity and nicotine expectancies.  For example, one study looked at the 
association between smoking outcome expectancies and three lower order factors on the 
ASI (Zvolensky, Feldner, Leen-Feldner, Bonn-Miller, McLeish, & Gregor, 2004).  They 
found that physical and mental incapacitation were significantly associated with outcome 
expectancies for negative affect reduction and negative personal consequences.  In a 
follow-up study, Zvolensky, Bonn-Miller, Feldner, Leen-Feldner, McLeish, & Gregor 
(2006) found that both physical and mental incapacitation concerns were associated with 




Stimulation, Relaxation, and Sensorimotor).  Moreover, these factors were associated 
lower levels of self-confidence about remaining abstinent when emotionally distressed.  
These findings persisted even after controlling for nicotine dependence, average number 
of cigarettes smoked per day, and gender. 
In terms of smoking cessation, an early study by Zvolensky, Feldner, Eifert, & 
Brown (2001) looked at anxiety related emotional reactivity to 20% carbon dioxide 
enriched challenge, a procedure which has been shown to elicit a panic-related arousal 
state.  They found that elevated emotional reaction to this challenge was negatively 
correlated with duration of smoking cessation abstinence among smokers with no history 
of panic related psychopathology.  In addition, Brown and colleagues (2001) found that 
higher scores on the ASI were predictive of increased risk of smoking lapse during the 
first week of abstinence.  In a related study, Zvolensky, Baker, Leen-Feldner, Bonn-
Miller, Feldner, & Brown (2004) examined the associations between anxiety sensitivity 
and retrospective nicotine withdrawal symptoms in a group of 127 habitual smokers.  
They found that anxiety sensitivity predicted the severity of retrospectively recalled 
withdrawal symptoms during the first week of their latest quit attempt.  Therefore, these 
results seem to suggest that individuals who are elevated in anxiety sensitivity may have 
difficulty quitting due to their inability to tolerate the withdrawal symptoms associated 
with smoking cessation.  
 Although the research in the area of anxiety sensitivity and smoking is quite new, 
preliminary results do suggest that individuals with elevated levels of anxiety sensitivity 
may smoke as a means to manage negative moods, expect that smoking will alleviate 




weeks due to their inability to tolerate the anxious withdrawal symptoms associated with 
smoking cessation. 
HPA Reactivity/Cortisol 
 Research in smoking behavior has become increasing focused on the effects of 
nicotine abstinence on the biobehavioral systems involved in the stress response.  In 
particular, the hypothalamic-pituitary-adrenal axis (HPA), and more specifically its 
primary hormone cortisol have been shown to play an important function in smoking 
relapse both through their effects on withdrawal symptoms and ability to effectively deal 
with stress.  A number of studies have demonstrated that acute nicotine intake causes an 
elevation in cortisol concentrations (e.g. Gilbert, Dibb, Plath, & Hyane, 2000;  
Kirschbaum, Wust, Strasburger, 1992; Mendelson, Sholar, Goletiani, Siegel, & Mello; 
2005; Pomerleau & Pomerleau, 1990a; Seyler, Pomerleau, Fertig, Hunt,  & Parker, 1986; 
Thakore, Berti, Dinan, 1999; Wilkins, Carlson, Van Vunakis, Hill, Gritz, & Jarvik, 1982; 
Winternitz & Quillen, 1977).  In addition, although the findings are less consistent, there 
is also evidence of increased basal levels of cortsiol in habitual smokers (Canal, 
Colomina, Domingo, & Domenech, 1997; del Arbol 2000; Field, Colditz, Willet, 
Longcope, & McKinlay, 1994).  As a result, it is reasonable to assume that abstinence 
from cigarette smoking would be associated with a rebound decrease in cortisol levels.  
In fact, a number of studies do support this hypothesis and demonstrate a sharp decrease 
in cortisol concentrations following even a short abstinence from nicotine (Pomerleau, 
Pomerleau, & Marks, 2000; Meliska, Stunkard, Gilbert, Jensen, & Martinko, 1995).  
Moreover, there is evidence that these changes in cortisol levels persist for extended 




Puddey, Vandongen, Beilin, & English, 1984; Steptoe & Ussher, 2006).  However, it is 
also important to note that not all studies have found this effect (al’Absi, Amunrund, & 
Wittmers, 2002; Benowitz, Kuyt & Jacob, 1984; Hughes, Arana, Amori, Stewart, & 
Workman, 1988; Pickworth & Fant, 1998; Teneggi et al., 2002).  However, many of 
these studies were limited by methodological issues (e.g. measurement and sampling 
issues) and the overall consensus in the literature supports the contention that nicotine 
withdrawal is followed by a decrease in cortisol concentrations both long and short term.  
 As noted earlier, smoking cessation is associated with a number of unpleasant 
withdrawal symptoms such as dysphoria, anxiety, irritability, difficulty concentrating, 
restlessness, appetite dysregulation, weight gain, and insomnia (American Psychiatric 
Association, 1994; Hughes, 1992, Hughes, Gust, Skoog, Keenan, & Fenwick, 1991; 
Hughes and Hatsulami, 1986).  Incidentally, this symptom profile is similar to that 
experienced during episodes of acute stress (Hughes 1992, Selye, 1976).  This has lead 
some to the hypothesis that the sudden drop in cortisol following abstinence from 
smoking may serve as a marker of intensity of withdrawal symptoms and dependence, 
and can potentially lead to an increased risk of relapse possibly as a way to self-medicate 
and ameliorate these unpleasant symptoms (al’Absi, Hatsukami, Davis & Wittmers, 
2004; Piasecki,, Jorenby, Smith, Fiore, & Baker, 2003).  A number of studies seem to 
support the hypothesis that cortisol levels following nicotine abstinence are associated 
with withdrawal symptoms both in the immediate period following cessation (Cohen, 
al’Absi, & Collins, 2004), and up to several weeks post-quit (Frederick et al., 1998; 
Ussher et al, 2006).  In addition, it appears that the delta (i.e. change) between baseline 




(Frederick et al., 1998).  In addition, al’Absi and colleagues (2004) looked at the role of 
cortisol levels on mood states and withdrawal symptoms during the first 24-hours of 
abstinence in predicting early smoking relapse (i.e. < one week).   They found that 
although all smokers experienced significant withdrawal symptoms and changes in 
diurnal cortisol levels, early relapsers evidenced a greater decline in morning cortisol 
concentrations along with greater withdrawal symptoms, cravings, and distress compared 
to those who maintained abstinence.  Therefore, although there have only been a small 
handful of studies that have directly examined the association between cortisol and 
symptoms of distress and withdrawal, it appears that the cortisol decrease following 
smoking abstinence may represent a marker of intensity of withdrawal effects and 
contribute to risk of early relapse. 
 Finally, it has been found that stress is an important risk factor for smoking 
relapse (e.g. Cohen & Lichenstein, 1990; Shiffman et al., 1996; Wills et al., 2002).  
Because cortisol and the HPA axis are heavily implicated in the stress response it is 
hypothesized that the chronic effects of nicotine may inhibit the HPA axis from 
responding adequately to other challenges (Al’Absi, Wittmers, Erickson, Hatsulami, & 
Crouse, 2003).  In addition, because smoking cessation is associated with a decrease in 
cortisol concentrations, and cortisol production is an important component of the stress 
response this decline may make it difficult for the individual to mount an effective stress 
response which can leave an individual vulnerable to relapse in the absence of other 
possible coping mechanisms.  There is some evidence to suggest that abstinence from 
smoking causes a hyporesponsiveness towards stress in habitual smokers (al’Abis 2003) 




Wittmers 2002).  In addition, there is some evidence to suggest that these alterations in 
the stress response contribute to or mediate the stress-withdrawal symptoms associated 
with smoking cessation and relapse.  In particular, al’Absi and collegaues (2005) 
examined the extent to which cardiovascular and cortisol response to stress during initial 
nicotine withdrawal predicted early relapse.  They had smokers who had been abstinent 
for 24-hours complete a series of psychological stressors (e.g. public speaking and 
cognitive challenges) and found that men (but not women) who relapsed within four 
weeks evidenced an attenuated cortisol response to stress compared to male abstainers.  
In addition, those who relapsed also showed reduced blood pressure response to stress, 
exaggerated withdrawal symptoms and mood deterioration.  Moreover, these responses 
predicted relapse even when controlling for baseline smoking and psychological 
measures, suggesting that an altered stress response at least partially due to changes in 
cortisol concentrations in men (but not necessarily women) is associated with an 
increased vulnerability for smoking relapse.  Therefore, although the literature is scant, 
there is some suggestion that the decline in cortisol concentrations following nicotine 
withdrawal may interact with a hyporesponsiveness to stress that can be predictive of 
early relapse. 
 Overall, the results of numerous studies provide evidence to suggest that the HPA 
axis, particularly cortisol plays an important role in smoking relapse.  Cortisol has been 
shown to increase following acute and habitual nicotine intake.  In addition, there is 
evidence that smoking cessation is associated with a rebound decrease in cortisol which 
may serve as a marker of dependence and be associated with withdrawal symptoms and 




relationship between this decrease in cortisol levels, withdrawal symptoms, 
hyporesponsiveness to stress and subsequent smoking relapse.  
Distress Tolerance 
 Distress tolerance is broadly defined as the ability to experience and withstand 
negative psychological states (Linehan, 1993).  Although its roots are in the area of affect 
regulation in borderline personality disorder (BPD), in recent years it has been subject to 
increased attention in the area of substance use and relapse.  As we have discussed, 
smoking relapse is associated with a number of unique predictors, however in some 
individuals it may not be the presence of these risk factors specifically, but rather the 
individual’s ability to tolerate them during a quit attempt that determines early smoking 
relapse.  For example, an individual’s ability to withstand the initial psychological and 
physical stress and discomfort associated with smoking cessation and everyday life may 
be a key determinant in whether or not that individual remains abstinent or lapses back 
into smoking as a way to ameliorate these feelings of discomfort. 
 Eisenberger’s (1992) theory of learned industriousness provides a conceptual 
framework for researchers to examine the relationship between an individual’s ability to 
tolerate discomfort and smoking cessation outcome.  Learned industriousness theory 
posits that the amount of effort (i.e. aversive, subjective experience that occurs when 
information processing, physical motion, or both are obstructed or fatigued) that an 
individual is willing to exert is dependent upon the degree of aversiveness associated 
with the task, which is a function of prior learning history.  Therefore, learned 
industriousness is a learning based theory of motivation that posits that individuals with a 




than these with a history of being rewarded for low effort who will regard the task as 
being highly aversive.  Specifically, quitting smoking can be viewed as a high-effort task 
that often times requires several attempts before being successful.  Moreover, ex-smokers 
must utilize a variety of cognitive and behavioral coping skills in order to successfully 
avoid smoking and effectively deal with the withdrawal symptoms, cravings, and 
negative affect that often accompanies early nicotine withdrawal.  According to the 
learned industriousness theory, those ex-smokers with a history of being rewarded for 
high effort will be more likely to persist in employing these alternative coping skills 
compared to those with reward histories of low effort.  Moreover, those individuals who 
exhibit high levels of effort may be more likely to delay the immediate reinforcement of 
smoking (i.e. the pharmacological aspects of smoking) in exchange for the delayed but 
long-term reinforcement of good health.  
 There have been several studies which demonstrated a relationship between the 
ability to tolerate discomfort and smoking cessation.  For example, a series of studies by 
Hajek and colleagues (Hajeck, 1991; Hakeck, Belcher, & Stapleton, 1987; West et al., 
1989) found that breath-holding duration, a measure of physical discomfort was 
significantly correlated with duration of subsequent smoking abstinence.  However, 
Quinn, Brandon and Copeland (1996) were the first to apply the theory of learned 
industriousness (as defined by task persistence) to smoking relapse.  Fifty-two heavy 
smokers (i.e. >20 cigarettes per day) and 57 nonsmokers participated in two 
psychologically distressing tasks, the anagram persistence task (APT) and the mirror 
tracing persistence task (MTPT).  The anagram persistence task (APT; Eisenberger & 




mirror-tracing persistence task (MTPT) is a stressor task that requires the subject to trace 
the outline of a geometric figure while viewing it through a mirror.  Results indicated that 
nonsmokers were more persistent than smokers on the APT and the MTPT, and that 
histories of drug and alcohol abuse were inversely related to task persistence.  However, 
it is important to note that this study used a cross sectional design so the results are 
correlational in nature.   
Because prospective or experimental designs are necessary to determine the 
direction of causality, Brown, Lejuez, Kahler, & Strong (2002) looked at the role of 
distress tolerance in predicting early smoking relapse in a group of 32 current smokers.  
Based on their retrospective reporting of past quit attempts, participants were divided into 
two groups; those smokers who had completed at least one sustained quit attempt lasting 
three months of longer (delayed relapsers), and those who had failed to quit smoking for 
more than 24 hours (immediate relapsers).  All participants were exposed to a mental 
arithmetic stressor (PASAT) and two physical challenges consisting of a breath holding 
task and inhalation of carbon dioxide enriched air.  These tasks were performed during 
both a normal ad libitum smoking day and following a 12-hour smoking abstinence.  
Results indicated that immediate relapsers endorsed higher levels of baseline depressive 
symptoms, a greater tendency to react to stress with negative affect, and higher increases 
in dysphoria and the urge to smoke following the 12-hour nicotine deprivation.  
Furthermore, immediate relapsers exhibited less behavioral persistence compared to 
delayed relapsers.  These results suggest that these individuals may be particularly 
vulnerable to early smoking relapse due to increased emotional distress in response to 




psychological discomfort.  In a second study (Lejuez, Zvolensky, Leen, & Feldner, 
2001), task persistence on the PASAT was compared to retrospective reports of previous 
smoking cessation attempts ranging from several hours to six months.  Longest cessation 
duration was positively associated with task persistence even after controlling for 
nicotine dependence.  
While these studies provide good initial evidence that distress tolerance plays a 
role in smoking relapse, prospective studies are necessary to determine the predictive 
ability of distress tolerance.  A study by Brandon and colleagues (2003) used the same 
methods employed in the Quinn and Brown (1996) study but utilized a longitudinal 
design.  All subjects participated in a pretreatment assessment of task persistence using 
the APT and MTPT before receiving a six session cognitive-behavioral smoking 
cessation treatment and a nicotine replacement therapy.  Following the treatment, 
subjects were divided into three groups; treatment non-completers, those who completed 
treatment but relapsed, and those who remained abstinent until follow-up.   They found 
that task persistence on the MTPT (but not the APT) predicted smoking abstinence across 
12 months above and beyond other significant predictors such as gender, nicotine 
dependence, negative affect, and self-efficacy.  In a more recent study, Brown and 
colleagues (2004) administered the PASAT, breath-holding and CO2 challenge tasks to a 
group of 81 smokers who were attempting to quit smoking on their own.  They found that 
although about 20% of the subjects were able to remain abstinent during the full 28-day 
follow-up, almost 65% lapsed within the first week.  In addition, those individuals who 
lapsed and were not able to remain abstinent demonstrated a lower level of persistence on 




Moreover, proportional hazard models showed that those individuals low in task 
persistence had a 2.94 time greater risk of lapsing over the course of the 28-day follow up 
compared to those with high task persistence, and 1.75 times greater risk compared to 
those with average levels of persistence.   
Although distress tolerance is a relatively new construct with respect to smoking 
research, results from a handful of studies suggest that it plays an important role in early 
smoking relapse.  Its effects have been demonstrated both retrospectively and 
prospectively, and persist regardless of whether the individual self-quits or enlists in a 
formal smoking treatment program.  However, it is important to note that these various 
studies are all limited to some degree.  For example, the early studies on distress 
tolerance were cross sectional in nature and considered past quit attempts, while the 
prospective studies focused on self-quitters (Brown et al., 2006).  In addition, these later 
studies tended to be limited to assessing psychological distress tolerance.  As a result, 
they failed to include other measures of distress tolerance and other relevant variables 
(e.g. anxiety sensitivity, cortisol) which help provide a more comprehensive picture of 
distress tolerance and its unique relationship to relapse (Brandon et al., 2005).  
Statement of Problem  
Despite increased awareness of the dangers of smoking and broad-based public health 
efforts to promote smoking cessation, over 44.5 million Americans continue to smoke 
regularly (CDC, 2005b).  Although smoking treatments significantly improve the success 
of quitting when compared to self-quitting, relapse rates are still high.  In addition, many 
individuals who attempt to quit, lapse within a few days, and many of these individuals 




it is imperative to understand the significance of the early smoking lapse and isolate 
factors specific to this subgroup of individuals that makes it difficult for them to quit 
smoking.  Although a number of variables such as withdrawal symptoms, negative affect 
and anxiety sensitivity have been found to play a role in early smoking relapse, the exact 
mechanisms underlying these factors that contribute to relapse is still unclear.  One 
particular hypothesis is that it is not necessarily the presence of any of these individual 
factors, but rather how the individual reacts to, and tolerates them that may be a key 
contributing factor of relapse.  Therefore, for some individuals it may be an inability to 
tolerate the withdrawal symptoms and negative affect associated with smoking cessation 
that leads to the initial smoking lapse and subsequent relapse as a way to cope with or 
ameliorate their distress.  This threshold for tolerating physical and psychological stress 
is known as distress tolerance.  
While early evidence has suggested that distress tolerance is associated with 
duration of smoking quit attempts, to date, no study has examined the effects of distress 
tolerance across physical, psychological, and biological domains on a number of other 
relapse predictors (e.g. negative affect, anxiety sensitivity and withdrawal symptoms) in 
determining smoking outcome.  Therefore, the following study looked at the role of these 
variables in predicting smoking outcome in a group of 58 smokers participating in a 
smoking cessation study.  Specifically, each participant completed a battery of distress 
tolerance measures including two psychological distress tolerance tasks, two physical 
challenges, a self-report measure of distress tolerance, and a measure of HPA reactivity.  
Participants then received the Nicoderm CQ nicotine patch in conjunction with an 8-week 




abstinence.  As such, this study provides a comprehensive picture of the role of distress 
tolerance in an ecologically valid way by using both behavioral and NRT smoking 
treatment components as indicated by Fiore and colleagues (2000).  Results from this 
study have important treatment implications in terms of identifying smokers at high risk 
for early smoking relapse and developing novel pharmacological and psychosocial 






1.  Early lapsers will evidence higher levels of negative affect (as measured by state 
negative emotionality, depressive symptoms and anxiety sensitivity) compared to 
delayed lapsers. 
 
2. Early lapsers will exhibit higher levels of negative affect-related withdrawal 
symptoms in response to smoking abstinence compared to delayed lapsers. 
 
3. Early lapsers will demonstrate lower levels of distress tolerance (as measured by task 
persistence and salivary cortisol) in response to a series of four laboratory challenge 
procedures and a self-report measure compared to delayed lapsers.  
 
4. Early lapsers will not differ from delayed lapsers in baseline state positive 
emotionality and withdrawal symptoms not related to affect  
 
5. Using a regression approach, distress tolerance across its various components will 
evidence incremental validity beyond negative affect-related withdrawal symptoms, 
depression, and anxiety sensitivity in the prediction of early smoking lapse.   
 
6. Self-report, behavioral and biological indices of distress tolerance will demonstrate 





Chapter 2: Methods and Procedure 
 
Participants 
Participants consisted of 58 adults with elevated depressive symptoms (M BDI at 
baseline = 9.89; SD = 7.55) who were motivated to quit smoking.  Participants were 
recruited as part of a larger study examining a novel behavioral activation treatment 
program for depressed smokers.  The final sample included 35 males and 23 females with 
a mean age of 44.7 years (SD=11.87).  The sample was predominately African American 
(75.4%) and Caucasian (19.3%), with 1.8% Hispanic/Latino, 1.8% Native American, and 
1.8% other.  With respect to education, 8.8% of participants completed some high school 
or less, 26.4% completed high school/GED, 45.6% finished at least some college or 
technical school, 5.3% graduated college, and 14.1% had at least some graduate 
education.  In terms of employment status, 42.8% of the sample was employed, 32.2% 
were unemployed, 9% were students, and 14.3% were retired.  Finally, with respect to 
smoking history, participants smoked an average of 17.4 (SD=8.5) cigarettes a day, had 




All participants completed a brief ten minute phone screen.  In addition to general 
demographic information, the screener also included questions related to smoking 
behavior, current use of any psychotherapy treatment or psychotropic medications, 




medical conditions.  During this phone screen, participants were also administered the 
Beck Depression Inventory-II (BDI) to assess for elevated depressive symptoms.  In 
order to be eligible for the larger treatment outcome study, participants needed to score a 
12 or higher on the BDI during their phone screen.  However, it is important to note that 
for the current study, BDI scores were not of particular interest and did not serve as an 
exclusionary variable.  Therefore, although many participants subsequently endorsed 
lower scores when they were given the BDI a few weeks later at baseline, this drift is not 
of concern for the current study.   
Beck Depression Inventory-II 
 The Beck Depression Inventory-II (Beck, Steer, & BrowI knon, 1996) is a 21 
item self report measure that assesses depressive symptoms over the past week.  
Questions are rated on a 4-point likert scale where a value of 0 means that the statement 
does not describe the individual at all and a value of 3 means that it describes them very 
well.  The individual’s total score is then used to determine the existence and severity of 
the depression.  According to the BDI-II, a score of 0-13 indicates minimal depression, 
14-19 is mild depression, 20-28 is considered moderate depression, and 29-63 indicates 
severe depression.  
 The BDI-II has been shown to be a reliable and well validated tool for the 
assessment of depressive symptoms.  Internal reliability is high, ranging from .89 to .93 
in student samples (Beck, Steer, & Brown, 1996; Steer & Clark, 1997; Whisman, Perez, 
& Ramel, 2000) to .89-.92 in psychiatric samples (Beck, Steer, & Brown, 1996; Steer, 
Rissmiller, & Beck, 2000).  Internal consistency of the BDI-II is good with a Cronbach 




criterion validity, with patients diagnosed with major depression scoring significantly 
higher on the BDI-II than those without depression (Arnau, Meagher, Norris, & Bramson, 
2001).  In addition, the BDI-II has evidenced good discriminant and convergent validity 
in that it correlates more strongly with measures of depression compared to measures of 
anxiety (Beck, Steer, & Brown, 1996). 
Structured Clinical Interview for DSM-IV (SCID 
 During intake, all participants were administered the Structured Clinical 
Interview for DSM-IV-non-patient version (SCID-NP; First, Spitzer, Gibbon, & 
Williams, 1995) to assess for current DSM-IV Axis I disorders present during the past 
year.  The SCID-NP is a clinician administered semi-structured clinical interview that 
provides coverage of all major DSM-IV Axis I disorders.  Because the measure is so 
comprehensive, the format of the SCID-NP utilizes a screener to determine which 
specific modules (each representing a distinct class of disorders) need to be covered, 
along with various skip-out instructions which allow the interviewer to leave a particular 
module once it becomes clear that the individual does not meet criteria for that particular 
diagnosis. 
 Studies on the psychometric properties of the SCID-NP have shown the measure 
to have good reliability and validity.  In terms of the reliability of the SCID-IV, test-retest 
reliability was found to range from poor (.35 for dysthymic disorder) to excellent (.78 for 
PTSD) for the various disorders (Zanarini et al., 2000).  In terms of validity, the SCID-IV 
has been compared to a best-estimate diagnosis using the LEAD standard (Spitzer, 1983) 
which includes a longitudinal assessment conducted by an expert diagnostician using all 




studies utilizing an approximation of this standard found superior validity of the SCID 
compared to standard clinical interviews (Basco et al., 2000; Kranzler et. al., 1996).   
Medical History 
 Participants also completed a brief medical history questionnaire that focused 
primarily on potential contraindications for using the nicotine patch (e.g. significant 
medical illness, cardiovascular illness, pregnancy, etc…).  In addition, all participants 
meet with the study physician for a brief physical to determine whether or not they were 
eligible to receive the nicotine patch.  In this sample there were no participants excluded 
from the study for medical reasons.   
Procedures 
Baseline Assessment 
 All participants who were deemed eligible following the initial phone screen 
were scheduled to complete the baseline assessment. Upon arrival for their baseline 
session, written informed consent was obtained and a trained graduate student 
administered the SCID-NP (Axis I), to determine if any DSM-IV psychopathology 
exclusion criteria were met.  Specifically, participants were excluded if they endorsed 
criteria for any current DSM-IV disorder or met criteria for any psychoactive substance 
use or dependence (excluding nicotine) within the last six months prior to coming to the 
study.  Individuals who were not eligible for the study were thanked for their 
participation, provided with mental health referrals if necessary, and given a self-help 
booklet on smoking cessation prepared by the National Cancer Institute (Clearing the Air; 




All laboratory tasks were conducted by the experimenter.  Prior to the initiation of 
the experimental tasks, baseline salivary cortisol readings were obtained.  The participant 
then engaged in each of the four distress tolerance tasks described in detail below.  These 
tasks included two psychological (i.e. PASAT, MTPT-C) and two physical (i.e. breath 
holding and Cold Pressor) stressors.  In order to increase motivation, participants were 
told that their performance on each task would influence the amount of money they could 
earn for the study and as such, they were instructed to try and do their best.  However, in 
reality this was not the true and all participants received the same compensation 
regardless of performance.  The order of the presentation of the various tasks was 
counterbalanced across participants to control for order effects.  Upon completion of the 
stressor tasks, the participants completed a variety of self-report measures.  Finally, 20 
minutes after completion of the last stressor task, the participants provided a second 
salivary cortisol sample to assess for HPA reactivity to stress.  Participants were paid $20 
at the conclusion of the study. 
Smoking Cessation Treatment 
Following their initial baseline assessment, participants completed one of two 
eight-week smoking cessation treatment groups.  Although both groups included standard 
behavioral treatment components (e.g. coping skills, social contracting, relapse 
prevention, relaxation), the experimental group also integrated elements of behavioral 
activation modified for smoking (i.e. pleasurable activity setting in line with a smoke-free 
lifestyle).  In addition participants in both groups received eight weeks of the Nicoderm 
CQ transdermal nicotine patch.  There were no significant differences between treatment 




condition was collapsed across groups.  Attrition was fairly high throughout treatment, 
with a drop out rate of almost 40% by quit day (week 4), and 46% drop out rate at the end 
of treatment (week 8).  These rates are consistent with other smoking cessation treatment 
studies which find high levels of attrition between baseline and initiation of treatment 
(30%-50%), with rates tapering off as treatment progresses (Curtin, Brown, & Sales, 
2000).  
Laboratory Tasks 
Paced Auditory Serial Addition Task (PASAT) 
All participants completed a modified computerized version of the Paced 
Auditory Serial Addition Task (PASAT; Diehr, Heaton, Miller & Grant, 1998; Lejuez, 
Kahler, & Brown, 2001), an addition task that has been shown to increase participants’ 
stress levels (Brown, Lejuez, Kahler, & Strong, 2002; Daughters, Lejuez, Bornovalova, 
Kahler, Strong, & Brown, 2005; Daughters, Lejuez, Kahler, Strong, & Brown, 20055; 
Deary, Ebmeier, MacLeod, Dougall, Hepburn).  During the task, numbers were flashed 
sequentially across a computer screen and participants were instructed to add the current 
number to the previously presented number.  They were then told to click on the correct 
sum using a keyboard provided on the computer screen.  The participant received one 
point for each correct answer with the total number of points earned displayed in a box on 
the right-hand side of the screen.  The task consisted of three levels which progress in 
terms of difficulty.  The first level of the PASAT lasted one minute and provided a three-
second latency between number presentations (i.e. low difficulty) while the second level 
lasted for two minutes level and provided a two-second latency (i.e. medium difficulty).  




second (i.e. high difficulty).  The third level lasted for up to seven minutes with the 
participant having the option to terminate the level at any time by clicking a quit button 
provided on the computer screen.  Distress tolerance was measured as the latency in 
seconds to task termination.  In addition, the number of points that the participant accrued 
over the course of the task was recorded to control for proficiency/skill on task 
persistence.  Finally, the experimental administration of a six item dysphoria scale 
occurred before the beginning of the task and at the end of the final level of the PASAT 
to determine if the task increased psychological stress.  This scale consisted of six single-
item ratings that were designed to assess moment-to-moment levels of anxiety, 
irritability, discomfort, and frustration (Brown et al., 2002).  A more detailed discussion 
of this scale is provided later.  
Computerized Mirror-Tracing Persistence Task (MTPT-C) 
 The Computerized Mirror-Tracing Persistence Task (MTPT-C; Strong, Lejuez, 
Daughters, Marinello, Kahler, & Brown, 2005) is a computerized version of the Mirror 
Tracing Persistence Task (MTPT; Quinn, Brandon, & Copeland, 1996).  For the MTPT-
C, participants were instructed to trace a dot along the lines of various shapes using the 
computer mouse.  However, to make the task similar to the original, the mouse was 
programmed to the move the red dot in the opposite direction than that showed on the 
screen (i.e. like a mirror).  Therefore, when the participant moved the mouse down, the 
red dot would move up, and so forth.  In order to increase the degree of difficulty and 
frustration, each time the participant moved the mouse out of the lines or stopped moving 
the mouse for more than two seconds, a loud buzzer sounded and the red dot moved back 




MTPT-C with each shape presented progressing in difficulty.  The first two rounds lasted 
one minute each while the third round of the MTPT-C lasted up to seven minutes.  
Participants were instructed that they had the option to terminate the task at any point 
during the third round by pressing on the space bar.  As with the PASAT, distress 
tolerance was measured by the latency in seconds to task termination.  Additionally, the 
number of errors per second (i.e., number of times the participant had to return to the 
starting position during the task divided by the task time) was recorded to control for the 
effects of skill on persistence.  Finally, the participant completed the dysphoria scale at 
both the beginning and end of the MTPT-C to determine if the task caused an elevation in 
psychological distress.  The original written version of the MTPT has been shown to 
increase stress (Matthews & Stoney, Tutoo, 1971) and has demonstrated good reliability 
(alpha = .92; Brandon et al., 2003). 
Physical Challenge: Breath Holding Task 
 Breath holding is a common task used to assess for physical distress tolerance and 
has been found to be predictive of length of time to smoking relapse (Brown et al., 2002; 
Hajek, Belcher, & Stapleton, 1987).  During this task participants were instructed to take 
a deep breath and hold it for as long as they can.  They were then asked to notify the 
experimenter when they began to feel uncomfortable by holding up a sign that signified 
they were feeling discomfort.  However, the participants were instructed to continue 
holding their breath beyond that point of initial discomfort for as long as possible.  
Distress tolerance was measured as the latency in seconds between when the participant 




safe and has been used in a previous large-scale study looking at distress tolerance in 
substance users (Daughters et al., 2005). 
Pain Challenge: Cold Pressor Task (CPT) 
 The cold pressor task is a commonly used measure of pain that involves having 
the participant submerge their hand in a bucket of freezing cold water (0-2 degree 
Celsius) a stimulus which produces a gradual escalation of pain (Shumate & 
Worthington, 1987; Willoughby, Hailey, Mulkana, & Rowe, 2002).  Similar to the breath 
holding task, the participant was instructed to notify the experimenter when they began to 
feel uncomfortable by holding up a sign that indicated so.  However, they were told to 
continue to keep their hand immersed in the cold water for as long as possible.  Distress 
tolerance was measured as the latency in seconds between when the participant began to 
feel uncomfortable and when they finally terminated the task by taking their hand out of 
the water.  
Self Report Measures 
Measures of Smoking History, Nicotine Dependence 
Smoking History. Smoking history was assessed at baseline using the smoking 
history and current status indices agreed upon by a National Cancer Institute consensus 
panel (Proceedings of the National Working Conference on Smoking Relapse, 1986).  
This included information such as: the rate of smoking, preferred brand of cigarette, 
nicotine content of preferred brand of cigarette, history and duration of previous quit 
attempts, number of household smokers, and age of onset of habitual smoking behavior.  
Fagerstrom Test for Nicotine Dependence (FTND). The Fagerstrom Test for 




served as a measure of nicotine dependence. The FTND has shown good internal 
consistency, a single dimension factor structure, and a positive relationship with degree 
of nicotine intake as assessed by saliva cotinine (Heatherton et al., 1991). The FTND is 
considered to be the standard instrument in the field for measuring nicotine dependence. 
Distress Tolerance 
 The distress tolerance scale (DTS; Simons & Gaher, 2005) is a self-report 
measure of emotional distress tolerance.  The questionnaire consists of 15 items designed 
to assess the individual’s ability to tolerate emotional distress, their subjective appraisal 
of distress, degree to which their attention is absorbed by negative emotions, and 
regulation efforts to alleviate distress.  Individual items are rated on a 5-point likert scale 
with higher scores being indicative of higher distress tolerance.  Data on the 
psychometric properties of the DTS show that the measure demonstrates adequate 
reliability and validity.  For example, the DTS exhibits good internal consistency with an 
alpha of .89 (Simon & Gaher, 2005).  In addition, the measure exhibited good test-retest 
reliability (r= .61) over the course of a six month period (Simon & Gaher, 2005).  In 
terms of validity, the DTS demonstrated expected associations with other measures of 
affective functioning supporting its convergent and discriminant validity.  Criterion 
validity was established by evidence of significant negative correlations with measures of 
substance abuse coping, but not enhancement motives (Simon & Gaher, 2005). 
Affective States 
Beck Depression Inventory-II (BDI). The Beck Depression Inventory-II was used 
to assess for current elevations in depressed mood.  A brief summary of the scale and its 




Positive and Negative Affect Schedule. For a baseline measure of positive and 
negative affect, this study used the 20-item Positive and Negative Affect Schedule 
(PANAS; Watson, Clark & Tellegen, 1988). This instrument has shown good internal 
consistency and discriminant and convergent validity (Crawford & Henry, 2004). 
Revised Anxiety Sensitivity Index (ASI-R). Anxiety sensitivity was measured via 
self-report using the Revised Anxiety Sensitivity Index (ASI-R; Taylor & Cox, 2001). 
The ASI-R is a 36-item self-report scale that uses a 5-point likert scale (0=very little to 
4= very much) to assess fear of anxiety related symptoms.  Anxiety sensitivity is 
measured across four factors including: fear of respiratory sensations, fear of publicly 
observable anxiety reactions, fear of cognitive dyscontrol, and fear of cardiovascular 
sensations.   The ASI-R has been used extensively and has sound psychometric 
properties.  In particular it has been found to have excellent internal consistency (alpha = 
0.94) and adequate validity (Deacon, Abramowitz, Woods, & Tolin, 2003) in a 
nonclinical college sample. 
Nicotine Withdrawal Symptoms 
 Withdrawal symptoms following smoking cessation were assessed weekly 
throughout treatment.  Symptoms were measured using the Shiffman-Jarvik Smoking 
Withdrawal Questionnaire (Shiffman & Jarvik, 1976).  This self-report measure consists 
of 25 items rated on a 7-point likert scale.  This questionnaire has been used in previous 
smoking studies and has been shown to be a reliable and sensitive measure of the 
duration, severity, frequency, and temporal variability of nicotine withdrawal symptoms.  





Task persistence served as a behavioral measure of distress tolerance on each of 
the four laboratory challenge tasks and was measured as latency in seconds to task 
termination. 
Dysphoria 
A series of single-item questions rated on a Likert scale ranging from 0 (none) to 
100 (extreme) were used to assess moment-to-moment levels of anxiety, irritability, 
discomfort, and frustration (Brown et al., 2002). These items were selected on the basis 
of their relevance for sensitivity to psychological distress.  A total score was derived by 
summing the score on each item to obtain measurement of general. 
Biological Measure 
Cortisol. In order to examine the role of biological arousal, an indices thought to 
be related to distress intolerance, salivary cortisol samples were obtained at baseline and 
20 minutes after the final laboratory challenge.  The baseline sample of cortisol gave an 
indication of baseline cortisol/HPA functioning while the 20 minute sample provided 
information on peak HPA reactivity.  HPA reactivity was defined as the difference in 
cortisol levels between the two collection points.  Cortisol samples were immediately 
frozen and sent to Salimetric Inc (State College, PA) for cortisol level determination by 
radioimmune assay. 
Measures of Smoking Status 
Timeline Follow-back Calendar 
A self report measure of smoking status was obtained from participants on their 
quit day and during their 1, 2, and 4-week post-quit day follow-ups.  Specifically, all 




assess for any cigarette use since the previous follow-up.  In addition, for those 
individuals who did not remain abstinent, the TLFB was used to assess the time to first 
smoking lapse.  The TLFB procedure has demonstrated good reliability and validity with 
adult alcoholics (Sobell & Sobell, 1979; 1980; 1996) and has recently been validated for 
the assessment of adult cigarette use (Brown et al., 1998).   
Biochemical Verification of Smoking Status 
For cases of self-reported abstinence a carbon monoxide analysis of breath 
samples was used to verify abstinence (Jarvis, et al., 1987).  Expired air carbon monoxide 
levels were assessed using the Bedfont Micro 4-Smokerlyzer carbon monoxide monitor.  





Chapter 3: Results 
Relationships among Distress Tolerance Measures  
Descriptive statistics for each distress tolerance and affect measure as well as the 
correlations among these measures are discussed below and these correlations are 
presented in Table 1. 
Psychological Distress Tolerance  
Overall, individuals persisted on the MTPT-C for an average of 297.5 seconds 
(SD = 144). The mean level of dysphoria increased following the MTPT-C (M = 30.1; SD 
= 28.3) compared to the assessment prior to the task (M = 14.6; SD = 18.5; t(57)= -5.68, p 
<.001], suggesting the task was considered psychologically stressful by the participants.   
To control for skill on the MTPT-C, the number of errors per second (EPS) was 
calculated by dividing the MTPT-C time by the number of errors.  There was a 
significant relationship between EPS and MTPT-C duration, such that individuals with 
fewer EPS tended to persist on the task longer than those with more EPS [r(58) =- .339, p 
<.01]. Given this finding, EPS was used as a covariate in further analyses to partial out 
the effect of skill on persistence.  
With respect to the PASAT, individuals persisted on the task for an average of 
286 seconds (SD = 160.3).  The mean level of dysphoria at the start of the task was 16.8 
(SD = 16.4) and at the end of the task was 30.8 (SD = 24.6).  The overall difference in 
level of dysphoria following administration of the task was statistically significant [t(56) 
= -5.64, p <.001], suggesting that the task was psychologically stressful to the 




on the second level was used.  There was no significant relationship between the number 
of correct responses and PASAT duration (p > .05). 
Correlations were then calculated to determine the relationship between the two 
psychological distress tolerance tasks.  As hypothesized, the MTPT-C and the PASAT 
were significantly correlated even after controlling for EPS on the MTPT-C, r(54) = .383, 
p < .01.   
Physical Distress Tolerance 
 Overall, participants persisted with the Breath Holding task (BH) for an average 
of 38.6 seconds (SD = 15.3).  The difference score was calculated by subtracting the time 
at which the participant first began to feel discomfort from their overall breath holding 
duration.  The mean difference score for BH was 12.4 seconds (SD = 7.7).  With respect 
to the Cold Pressor task (CP), the average amount of time they persisted on the task was 
56.8 seconds (SD = 48.8), and the difference score was 25.6 seconds (SD = 31.9).  
Correlations were then calculated to determine the relationship between the difference 
scores on the two physical distress tolerance tasks, and as hypothesized the two tasks 
were significantly correlated, r(56) = .633, p < .01.   
Physiological Distress Tolerance 
 Cortisol samples were obtained pre-and-post distress tolerance tasks and a 
difference level was obtained by subtracting the pre-task levels from the post-task levels 
to get a measure of cortisol change as a result of the tasks.  The mean cortisol difference 
level was -.02 (SD = .05).  The cortisol difference level was significantly positively 
correlated with MTPT-C quit time, r(53) = .387, p < .01 and negatively correlated with 




the greater the cortisol difference (i.e. the greater the spike in cortisol following the four 
behavioral tasks), the longer the subject persisted on the MTPT-C, and the less time they 
persisted on the Cold Pressor. 
Distress Tolerance Scale Self-Report 
The overall score on the DTS was 3.3 (SD = .82).  With respect to the four 
subscales, the means were as follows: Tolerance 2.9 (SD = 1), Regulation 3.2 (SD = 1), 
Appraisal 3.5 (SD = .87), and Absorption 3.5 (SD = 1).  As expected the four DTS 
subscales were all significantly correlated with one another (see Table 1).  
Relationships among Affective Self-Reports and Distress Tolerance Measures 
The relationship among affective self-reports measures and distress tolerance is 
also presented in Table 1.  There were no significant relationships between the self-report 
measures and measures of psychological or physiological distress tolerance.  There were 
several significant correlations between affective and physical distress tolerance 
measures.  There were significant negative correlations between the BH difference score 
and negative affect withdrawal symptoms (r = -.39, p < .05), and the PANAS PA scale (r 
= -.31, p <.05).  There was also a positive relationship between BH difference score and 
non affect-related withdrawal symptoms (r = .53, p < .01).  Finally, there was also a 
significant relationship between the CP difference score and non-affect related 
withdrawal symptoms (r = .39, p < .05).  With respect to the DTS, there were significant 
negative correlations between the DTS total score and the BDI (r = -.47, p < .01) and the 
ASI (r = -.58, p < .01).  The BDI and the ASI-R were also negatively correlated with each 
of the four DTS subscales (see Table 1).  These negative correlations suggest that as the 




A number of the affective self-report measures were significantly correlated with 
one another.  Specifically, the BDI was correlated with the ASI-R (r = .41, p < .01) and 
the PANAS NA scale (r = .48, p < .01).  The ASI-R was also correlated with the PANAS 
NA scale (r = .34, p < .05).  Finally, negative withdrawal symptoms was negatively 
correlated with non-affect related withdrawal symptoms (r = -.63, p < .01).  
Smoking Status  
Smoking abstinence was analyzed using a categorical measurement of early 
smoking lapse (< 3 day).  Participants were separated into groups based upon those who 
endorsed having a smoking lapse within three days of quitting (early lapsers; n=34) and 
those who abstained from cigarettes for three days or longer (delayed lapsers; n=24).  
These categories were chosen based on findings from the smoking cessation literature 
which has found that many individuals who attempt to quit smoking lapse within the first 
few days of their quit attempt (e.g. Gulliver, Hughes, Solomon, & Dey, 1995; Hughes, 
Keely, & Naud, 2004).  Table 2 presents the frequency distribution for the number of 
days until first lapse.  
A separate set of analyses was initially planned to compare those participants who 
remained abstinent at least 30 days to those who relapsed.  However, only six of the 58 
participants (~10%) endorsed not smoking for at least one month which resulted in a 
sample to small to yield adequate power.  
Mean Differences between Early and Delayed Lapsers 
Demographic and Smoking History 
 Table 3 presents differences between early and delayed lapsers with regards to 




of years smoking, current number of cigarettes, and number of past quit attempts.  
Annual household income was assessed using an 11-point likert scale ranging 1 to 11 
with each level representing $10,000 increments, such that 1 represented $0-$9,999 and 
11 represented $100,000 or more.  These ratings were then separated into three groups for 
ease of analyses.  With respect to employment status, individuals were categorized as 
employed if they endorsed either full or part-time working status.  These individuals who 
endorsed being unemployed, a student, homemaker, or retired were categorized as 
unemployed.  Finally, education level was assessed using a 10-point likert scale where 1 
represented no education and 10 represented a graduate or professional degree.  Again, 
for ease of analysis participants were divided into three categories which included some 
high school education or lower, high school graduate/GED, and some college and 
beyond.   
There were no significant differences between early and delayed lapsers on any 
demographic variables.  With respect to smoking history, there was a significant between 
group difference on current number of cigarettes smoked (p < .05), with early lapsers 
endorsing smoking more cigarettes per day at baseline than delayed lapsers.  Therefore, 
this variable was controlled for in subsequent analyses. 
Affective Self-report Measures 
 Mean differences between early and delayed lapsers on affective self-report 
measures are presented in Table 4.  There were no significant between group differences 
on measures of general negative and positive affect, depression, anxiety sensitivity, and 
withdrawal symptoms.   




 Group differences between the various measures of distress tolerance are 
presented in Table 4 and Figures 1-4.  There were no significant between group 
differences on any of the DTS scales, MTPT-C and cortisol difference levels.  However, 
there were significant differences on the PASAT, F (1, 55) = 9.12, p < .01, CP difference 
score, F (1, 53) = 6.53, p < .05,  and BH difference score F (1, 53) = 4.26, p < .05, such 
that early lapsers displayed shorter task persistence on these measures compared to 
delayed lapsers.  
Predictors of Smoking Abstinence  
To determine the extent to which each significant distress tolerance measure 
predicts smoking outcome, a logistic regression analysis was conducted and results are 
presented in Table 5.  Prior to analyses, all non-dichotomous variables were centered as 
way of reducing multicolineraity.   In the first step of the model gender and average 
number of cigarettes smoked per day were entered.  Although there was no significant 
difference between the two groups on gender, it was included in the model because it has 
been shown to be related to length of smoking abstinence (Wetter et al., 1999).  The 
second step of the model included PASAT quit time and a composite score of physical 
distress tolerance (PHYSICAL) that was created by adding the z scores of the BH and CP 
difference scores.  Overall, the first step of the model was not significant, X2(2) = 4.67, p 
> .05, suggesting that the gender and number of cigarettes smoked per day do not reliably 
predict smoking status.  Upon entering the distress tolerance measures in the second step, 
the overall model was significant, X2(2) = 19.52, p < .001, and was able to correctly 
classify smoking status for over 69% of the participants.   Within this completed model 




.930), and PASAT quit time (Wald = 6.67, p = .01; OR = .994; 95% CI = .989-.998) were 






Means, standard deviations and intercorrelations among distress tolerance measures and affect self-reports 
 
Measure M(SD) 1 2 3 4 5 6 7 8 9 
 
10. 11 12 13 14 15 16 
1.  MTPT-C 297.5 (144) --- .36** .25 .12 .29* .20 .24 .27* .25 .38** -.26 -.23 -.12 -.00 .03 .13 
2. PASAT 286 (160.3)  --- .041 .10 -.03 -.06 -.11 .02 .06 -.06 -.10 -.20 -.07 -.07 -.11 -.13 
3. BH_diff 12.5 (7.7)   --- .63** .13 .12 .17 .10 .02 .14 -.04 -.19 .13 -.39* -.31* .53** 
4. CP_diff 25.6 (32)    --- .24 .19 .24 .19 .13 -.28* -.05 -.19 .19 -.34 -.22 .39* 
5. DTS_Total 3.3 (.82)     --- N/A N/A N/A N/A -.07 -.47** -.58** -.07 -.17 .23 .30 
6. DTS-Tol 2.9 (1)      --- .44** .56** .56** -.00 -.32* -.40** -.12 -.29 .13 .33 
7. DTS-Reg 3.3 (1)       --- .65** .49** -.08 -.28* -.57** .04 -.09 .05 .19 
8. DTS-App 3.6 (.87)        --- .71** -.01 -.44** -.49** -.14 -.08 .19 .23 
9. DTS-Absorp 3.6 (1)         --- -.11 -.52** -.45** -.06 -.08 .36* .28 
10. Cort_diff -.02 (.05)          --- .03 .03 -.03 .06 -.18 .07 
11. BDI 9.89 (7.55)           --- .41** .48** .03 -.08 -.01 
12. ASI 20.6 (11.9)            --- .34* .03 .06 -.01 
13. PANAS NA 15.8 (5.85)             --- -.01 .07 .09 
14 Neg. Withdrawal 44.1 (7.31)              --- .20 -.63** 
15. PANAS PA 32.8 (8.55)               --- -.15 
16. Non-Affect. 
Withdrawal 
20.1 (5.65)                --- 
* p<.05; ** p<.01 
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Table 2:  
 
Frequency distribution table for number of days to first smoking lapse 
 
Days to First Lapse 
 
Frequency Percent Cumulative Percent 
0 
 
34 58.6 58.6 
3 
 
8 13.8 72.4 
7 
 
7 12.1 84.5 
14 
 
2 3.4 87.9 
21 
 
1 1.7 89.7 
            >28 
 
6 10.3 100 
Total 
 
58 100 --- 
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Table 3. 
 
Means and standard deviations of demographics and smoking history variables among 














44.7 (11.8) 44.8 (11.9) 44.7 (11.9) t(56)= .141, p=7.08 .008 
Gender (% Male) 
 
60.3% 50% 75% X 2(1)=3.67  
Ethnicity (% African American) 
 
74.4% 76.7% 75% X 2(1)=2.88  
Total Household Income 
 
        $0-$39,999 
 
        $40,000-$79,999 
 
        $80,000+ 
 


























Employment Status (% Unemployed) 
 
41% 37.5% 45.8% X 2(1)=7.08  
Education Level 
 
       Some High School or Lower 
 







































t(56)= .364, p=.549 .365 
Number of Cigarettes Smoker per 
Day at Baseline 
 
17.4 (8.5) 18.3 (10.4) 16 (4.7) t(56)= 6.54, p=.013* .285 
Number of Time Attempted to Quit 
 
3.8 (3.6) 3.7 (3.9) 3.9 (3) t(56)= .272, p=.604 -.05 
*p <.05 
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Table 4. 
 
Means, standard deviations, and group differences on self-report and distress tolerance  
 
measures between early and delayed lapsers 
 
 Early Lapsers 
 
Delayed Lapers   
Measure Mean SD Mean SD F Partial Eta 
Squared 
BDI Total Score 
 
10.96 8.11 8.45 6.62 1.33 .025 
ASI Total Score 
 
22.69 11.92 17.78 11.54 2.38 .045 
PANAS NA Scale 
 




47.33 5.72 42.71 7.60 2.48 .084 
PANAS PA Scale 
 




17.89 4.46 21 5.94 1.79 .062 
DTS Total Score 
 
3.27 .83 3.42 .83 .361 .007 
DTS Tolerance 
 
2.85 .98 3.17 1.12 1.27 .023 
DTS Regulation 
 
3.16 1.08 3.40 .99 .885 .016 
DTS Appraisal 
 
3.59 .92 3.56 .81 .048 .001 
DTS Absorption 
 
3.56 1.13 3.60 1.06 .000 .000 
MTPT-C 
 
288 146.84 311.13 141.83 .296 .005 
PASAT 
 
236.53 173.45 359.21 104.40 9.12** .144 
CP Difference Score 
 
17.28 20.93 36.75 40.37 6.53* .110 
BH Difference Score 
 




-.014 .062 -.018 .040 .085 .002 
*p<.05, **p<.01 
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Figure 1. 
 
Mean task persistence (seconds) between early and delayed lapsers on the PASAT and  
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Figure 2. 
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Figure 3. 
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Figure 4. 
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Table 5. 
 
Logistic regression analysis of immediate and delayed lapsers with covariates gender  
 











     
     Gender 
 
1.045 .601 3.025 2.84 .876-9.240 
    # Cigarettes/Day 
 
.043 .038 1.270 1.04 .968-1.126 
Step 2 
 
     
    Gender 
 
 .785 .686 1.312 2.19 .572-8.40 
    # Cigarettes/Day 
  
 .093 .049 3.59 1.09 .997-1.20 
    PASAT 
 
-.006 .002 6.67* .994 .989-.998 
    PHYSICAL -.664 .302 4.84** .515 .285-.930 
      
 
Note: CI = Confidence Intervals; *p =.010; **p=.02 
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Chapter 4: Discussion 
Despite its well documented dangers and a vast public health campaign, over 20% 
of Americans continue to smoke (CDC, 2005b).  Many smokers who attempt to quit, 
lapse within a few days, and many of these individuals ultimately resume smoking.  As 
such, it is imperative to understand the factors unique to early smoking relapse.  Although 
variables such as withdrawal symptoms, negative affect and anxiety sensitivity may play 
a role in early smoking lapse, the mechanisms underlying these factors are not fully 
understood.  One particular hypothesis is that it may not be the presence of any of these 
distress-related variables specifically, but rather how the individual reacts to and tolerates 
them that ultimately leads to smoking lapse.  This threshold for tolerating physical and 
psychological stress is known as distress tolerance.  The following study prospectively 
examined the role of these variables in predicting smoking outcome in a group of 58 
smokers participating in an eight-week smoking cessation treatment. 
Distress Tolerance 
 It was hypothesized that early lapsers would evidence lower psychological, 
physical, self-report, and biological levels of distress tolerance compared to delayed 
lapsers.  Results from this study provide partial support for this hypothesis.  As predicted, 
early lapsers evidenced lower levels of physical distress tolerance compared to delayed 
lapsers.  Moreover, this relationship remained significant even after accounting for other 
factors in this study related to early smoking lapse (i.e. gender, number of cigs per day).  
These positive findings are consistent with other studies which have found a relationship 
between behavioral tasks of physical distress tolerance and smoking abstinence using 
both cross sectional and prospective designs (Brown, Lejuez, Kahler, & Strong, 2002; 
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Hajeck, 1991; Hakeck, Belcher, & Stapleton, 1987; West et al., 1989).  However, the 
majority of studies which included a measure of physical distress tolerance have been 
limited to respiratory challenges such as breath holding and CO2 inhalation.  To date, 
only one other study has included the cold pressor task as a measure of physical distress 
tolerance (Daughters et al., 2005).  Specifically, they found that the cold pressor task was 
not related to early treatment drop-out from a residential drug treatment facility.  Aside 
from studying a different substance, this study only included those individuals who had 
been through detoxification or had been abstinent from drugs for at least 72 hours.  
Therefore, this sample was potentially biased towards individuals who demonstrated an 
ability to tolerate withdrawal symptoms long enough to make it into the facility.  On the 
contrary, the current study examined smokers prospectively through the early phase of 
their quit attempt when physical withdrawal symptoms would presume to be at their 
highest level (Cummings, Giovino, Jaen, & Emrich, 1985).     
With respect to the relationship between psychological distress and early smoking 
lapse, findings were mixed.  While there was a significant difference between early and 
delayed lapsers on the PASAT, there were no significant differences on the MTPT-C.  
Similar to the findings on physical distress tolerance, this relationship with the PASAT 
provided incremental validity above and beyond other smoking related factors.  While it 
was expected that both measures of psychological distress tolerance would predict time to 
smoking lapse, other studies have also found inconsistent results when using multiple 
measures of psychological distress tolerance (Brandon et al., 2003; Stipelman et al., 
2007).  For example, Brandon and colleagues (2003) found that persistence on the MTPT 
predicted smoking abstinence, while performance on a second measure of psychological 
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distress tolerance (the APT) did not.  There have been a few studies which have found a 
relationship between the PASAT and retrospective reports of smoking cessation (Brown, 
Lejuez, Kahler, & Strong, 2002; Lejuez, Zvolensky, Leen, & Feldner, 2001).  
Interestingly, the one study that looked prospectively at smokers across a self-quit 
attempt failed to find a relationship between the PASAT and smoking lapse/relapse 
(Brown et al., 2004).  However, it is important to note that this study followed 
participants across an unaided self-quit attempt.  It could be that without pharmacological 
aid, the physical withdrawal symptoms during a quit attempt may become more 
prominent (and ultimately lead to lapse) than the psychological withdrawal symptoms 
associated with smoking cessation.  
Contrary to expectations, persistence on the MTPT-C was not predictive of time 
till smoking lapse (though findings were in the right direction).  This runs contrary to 
other studies which have found the MTPT to be related to smoking status (Quinn, 
Brandon, and Copeland, 1996), treatment initiation and drop out (Brandon et al., 2003), 
and sustained smoking abstinence (Brandon et al., 2003; Stipelman et al., 2007).  One 
potential explanation for the lack of findings may have to do with the fact that this study 
used a computerized version of the MTPT rather than the paper version employed in 
other studies.  The nature of the computer program is such that it is virtually impossible 
to be successful on the task (as opposed to the paper version which is difficult, but not 
impossible).  Therefore, participants may have realized during the task that they had no 
chance of being successful which could have influenced how hard they tried and how 
long the persisted on the task.  Specifically, participants could have terminated the task 
slightly quicker than they would have if they had thought they could be successful.  
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One of the novel inclusions in this study was the use of the Distress Tolerance 
Scale (DTS), a self-report measure designed to assess emotional distress tolerance.  
Contrary to our expectations, there were no group differences between early and delayed 
lapsers on the DTS total score or any of its four subscales (Tolerance, Appraisal, 
Regulation, and Absorption).  While this was the first study which included a self-report 
measure specifically designed to assess distress tolerance, results from other studies 
which have used self-report measures of “persistence” have been equivocal (Etter et al., 
2003; Sabol et al., 1999, Steinberg et al., 2007).  For example, Steinberg and colleagues 
(2007) used two questions related to persistence from the Tridimensional Personality 
Questionnaire (TPQ; Cloninger, 1987) to compare smoking behavior in a large sample of 
adolescents.  They found higher persistence scores in nonsmokers compared to current 
smokers, and in those adolescents planning to quit versus those with no plans.  However, 
in this study persistence scores were not related to prior successful quit attempts.  These 
findings suggest that self-reports of distress tolerance and task persistence may not 
measure the construct in the same way as behavioral tasks.  In addition, individuals may 
have difficulty accurately reporting how persistent they are, whereas a behavioral task is 
able to produce a more objective measure. 
  It has been suggested that frequent and prolonged stimulation of the HPA-axis as 
a result of cigarette smoking may lead to reduced responsiveness of the system during 
times of stress (Kirschbaum, Strasburger, and Langkar, 1993).  Given that quitting 
smoking is viewed by many as a stressful experience, this attenuation of the stress 
response system may leave the individual ill equipped to handle the quit attempt.  As 
such, it was hypothesized that early lapsers would evidence lower salivary cortisol 
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difference scores following the distress tolerance tasks compared to delayed lapsers.  
However, contrary to our expectations, we did not find evidence of this relationship.  
There were a number of methodological limitations that could explain this lack of 
findings.  In particular, cortisol concentrations are influenced by a variety of factors apart 
from stress (i.e. smoking, natural diurnal variation, food, infection, etc...) that were not 
controlled for due to methodological constraints on data collection.  Therefore, it is 
plausible that more controlled collection of cortisol levels may have yielded different 
results.  However, it is also important to note that the literature is still unclear regarding 
the relationship between stress, smoking, and cortisol.  While a number of studies have 
shown attenuated cortisol levels in smokers during times of stress (Gilbert et al., 1996; 
Kirschbaum, Strasburger, & Langkrar, 1993; Rohleder & Kirschbaum, 2006), others have 
actually found the opposite result (Pomerleau & Pomerleau, 1990; Roy, Steptoe, & 
Kirschbaum, 1994).  Moreover, all of these studies compared smokers to nonsmokers and 
it may be that within smokers there is not enough variation to yield between group 
differences.  
Affect Related Variables 
 A number of studies have suggested a potential relationship between early 
smoking lapse and depression (Rausch, Nichinson, Lamke, & Matloff, 1990 ), negative 
affect (Kenford et al., 2002), and to a lesser extent withdrawal symptoms (Piasecki et al, 
2003a) and anxiety sensitivity (Brown, Kahler, Zvolensky, Lejuez., & Ramsey, 2001).  
Therefore, it was hypothesized that early lapsers would endorse higher levels of overall 
negative affect and affect related withdrawal symptoms compared to delayed lapsers.  
Contrary to our expectations, although findings were generally in the expected direction, 
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there were no significant differences between early and delayed lapsers on any affect 
related variables measured.  In order to be eligible for the larger treatment study, 
participants were required to evidence slightly elevated BDI symptoms (mean= 9.89).  
Furthermore, due to their significant correlation with one another, these increased BDI 
scores likely also lead to elevated NA PANAS scores.  Therefore, it is possible that this 
inclusion criteria lead to a lack of between group variability on these variables.  With 
respect to anxiety sensitivity, findings in the literature have been equivocal, and the lack 
of relationship in this study is consistent with others which have also failed to find a 
direct relationship between anxiety sensitivity and duration of smoking abstinence 
(Brown, Lejuez et al., 2001).  However, it is also important to note that ASI-R scores in 
this sample were fairly low across both groups which may have precluded any 
differences.  These same inconsistent findings have also been documented in negative 
affect related withdrawal symptoms (Patten & Martin, 1996).  The hypothesis that 
positive emotionality and withdrawal symptoms not related to affect (e.g. are you 
thinking of cigarettes more than usual?) would not differ between early and delayed 
lapsers was supported.  
It has been suggested that there is a relationship between distress tolerance and 
the various affect related variables described above (Brown, Lejuez, Kahler, & Strong, 
2002).  In particular, it may not be the presence of any of these factors per say, but rather 
how the individual responds to them that determines smoking lapse.  Therefore, it was 
hypothesized that distress tolerance would be significantly correlated with these affect 
variables.  Results from this study partially support this hypothesis.  Both the BDI and the 
ASI-R were significantly negatively correlated with the DTS and its subscales, such that 
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as BDI and ASI-R scores increased, DTS scores decreased.  This makes conceptual sense 
given the evidence suggesting that many individuals smoke as way to alleviate symptoms 
of depression and anxiety (Brown, Kahler, Zvolensky, Lejuez, & Ramsey, 2001; Lerman 
et al., 1996).  This may be particularly true for those smokers who have a difficult time 
experiencing and tolerating distressing emotions.  Interestingly, the BDI and ASI-R were 
not significantly related to any other distress tolerance measures.  
Also consistent with expectations, negative withdrawal symptoms were 
negatively correlated with Breath Holding difference score, suggesting that the more 
negative withdrawal symptoms the individual experienced on quit day, the less time they 
persisted holding their breath after experiencing discomfort during the behavioral task.  
Interestingly, there was no relationship with the Cold Pressor task or the self report and 
psychological measures of DT.  It could be that the type of physical discomfort caused by 
breath holding is more comparable to the type of negative physical withdrawal symptoms 
commonly experienced by smokers (e.g. headache, sweating, tingling), as opposed to the 
Cold Pressor which is simply a basic physical pain task.  Therefore, for the purposes of 
this study it is possible that the Breath Holding task was more ecologically valid than the 
Cold Pressor.  The lack of findings with respect to the psychological distress tolerance 
tasks was surprising, especially given the fact that many negative withdrawal symptoms 
are related to psychological discomfort (e.g. anxiety, irritability).  In terms of non-affect 
related withdrawal symptoms there was a significant positive relationship with both the 
Breath Holding and Cold Pressor difference scores, suggesting that more non-affect 
related withdrawal symptoms (e.g. do you feel awake? Is your appetite smaller than 
usual?) an individual experienced, the longer they persisted beyond the point of 
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discomfort on the two physical tasks.  Similar to the negative withdrawal symptoms, 
there were no significant findings on the self report or psychological distress tolerance 
measures. 
Finally, the PA PANAS score was positively correlated with the DTS Absorption 
scale, such that the greater the number of positive feelings checked off on the PANAS, 
the less likely the participant was to endorse feeling absorbed or functionally impaired in 
the face of distressing emotions.  This makes intuitive sense in that an individual who 
generally experiences positive emotions is likely to be someone who is able to cope 
effectively with distress and not let their negative moods overcome them.  Surprisingly, 
the positive score on the PANAS was negatively correlated with the BH difference score, 
suggesting that the more positive mood items an individual endorsed, the less likely they 
were to persist with holding their breath beyond the point of discomfort.  The reason for 
this discrepant finding is unclear and future examination is needed to determine if this 
inverse relationship actually exists or is merely an aberrant finding.  Contrary to 
expectations, there were no significant findings on the negative PANAS items and 
measures of distress tolerance.  Overall, these findings are suggestive of some association 
between affect related variables and distress tolerance, however, the exact nature of that 
relationship remains unclear.   
Convergent Validity 
One limitation in the distress tolerance literature has been the lack of consistency 
in the method of measurement of distress tolerance across studies.  While the majority of 
studies have used behavioral assessment tasks (as opposed to self-report and biological 
indicators) there is still considerable variability in the specific type of behavioral task 
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employed.  However, given that all these methods purport to measure distress tolerance, 
we hypothesized that we would find evidence of convergent validity across all domains 
of distress tolerance assessed.  One of the novel methodological elements of the current 
study was the use of multiple measures of psychological and physical distress tolerance.  
As hypothesized, we found high correlations within the psychological (PASAT, MTPT-
C) and physical (BH, CP) distress tolerance tasks suggesting adequate construct validity.  
However, we did not find significant correlations between the psychological and physical 
distress tolerance measures suggesting that the two types of measures are not redundant 
and may be capturing a different aspect of the distress tolerance construct.   
With regard to the DTS self report, as expected the DTS total score and its 
subscales were significantly correlated, suggesting that each of the subscales is capturing 
a related (though distinct) aspect of the distress tolerance construct (Simons & Gaher, 
2005).  When comparing the DTS to other measures of distress tolerance, there was a 
relationship between the MTPT-C and the DTS total score and DTS appraisal score, such 
that the more time one persisted on the MTPT-C, the more likely they reported greater 
ability to withstand and accept emotional/psychological distress.  While it makes sense 
that a self report measure of psychological distress tolerance would be related to 
behavioral measure of psychological distress tolerance, this finding was surprising given 
that the PASAT, and not the MTPT-C actually predicted time to smoking lapse.  One 
anecdotal possibility to account for these findings has to do with the nature of the two 
tasks.  While the PASAT is certainly a frustrating task, it is a working memory task that 
requires the ability to do simple math in your head quickly and accurately.  As such, 
individuals who have a weakness in math may have gone in with the attitude that they 
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were going to perform poorly on the task no matter what.  On the other hand, the MTPT-
C consists of tracing a shape, which is a seemingly less difficult task.  Therefore, it is 
possible that when participants had a difficult time completing the MTPT-C they felt 
especially frustrated and ashamed at their level of distress because tracing a shape felt 
like a task they should have been successful on.  Unfortunately the current study did not 
measure attitudes towards the given tasks so there is no way of knowing if their 
perceptions of the task influenced their level of frustration.  None of the other distress 
tolerance measures were significantly related to the DTS.  With respect to the physical 
distress tolerance tasks this lack of findings was not surprising given that the DTS is 
specific to emotional and psychological distress and does not include questions related to 
tolerance of physical discomfort.   
Finally, the cortisol difference score, which served as a biological indicator of 
distress tolerance, was significantly related to the MTPT-C and the Cold Pressor 
difference score.  However, the directionality was actually reversed for each of the tasks, 
such that the greater the cortisol difference score the longer the subject persisted on the 
MTPT-C, and the less time they persisted on the Cold Pressor.  As mentioned above, a 
handful of studies have found that smokers exhibit an increase in cortisol levels (possibly 
attenuated, but still elevated) following a psychological stress task (Kirschbaum, 
Strasburger, & Langkrar, 1993; Rohleder & Kirschbaum, 2006; Roy, Steptoe, & 
Kirschbaum, 1994).  Given these findings, it is logical to presume that the longer the 
participants persisted on the MTPT-C (a psychological stressor), the greater the expected 
elevation in cortisol level.  However, the contrary finding with respect to the Cold Pressor 
task is more puzzling.  The literature examining the role of smoking and stress on cortisol 
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response has been largely limited to the effects of a psychological stressor.  The one 
study examining the effects of physical stress and cortisol was conducted in nicotine 
dependent rabbits, where they found an increase in corticosterone following the 
application of a physical restraint stressor (Morse, 1989).  However, the effects of 
physical stress on cortisol levels in adult smokers is unclear.  For example, it is possible 
that initial experience of physical pain causes an immediate spike in cortisol levels that 
tends to decrease and habituate over time if the pain stimulus persists.  Unfortunately, the 
current study only assessed for cortisol levels at baseline and following the completion of 
all four behavioral tasks.  As such, it is impossible through this study to tease apart the 
unique variability in smoker’s cortisol levels following either a psychological or physical 
stressor. 
It is also interesting to note that the mean cortisol difference score was -.02, 
suggesting that a majority of the participants (33 out of 54) actually had a decrease in 
cortisol levels following the completion of the four behavioral tasks.  Although this 
finding was surprising, there is no clear consensus in the literature regarding the effects 
of stress on cortisol levels in smokers with some studies finding an elevation in cortisol 
levels (Pomerleau & Pomerleau, 1990b; Roy, Steptoe, & Kirschbaum, 1994) and others 
finding no effect or a blunted response (Gilbert, Stunkard, Jensen, Detwiler, & Martinko, 
1996; Kirschbaum, Strasburger, & Langkrar, 1993).  
Limitations and Future Directions 
 There are a number of noteworthy limitations in the current study.   First, with 
respect to the sample, the majority of participants (~75%) in this study were African 
Americans.  While certainly this is an important and underrepresented population to 
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study, the lack of heterogeneity precludes generalizability to the general population.  
Therefore, future research on this topic should include a more ethnically representative 
sample.  Moreover, the majority of participants came from a relatively low SES which is 
potentially important given the financial compensation associated with the project.  In 
order to be included in the study, participants needed to express a high degree of 
motivation to quit smoking.  While the mean level of motivation in the sample was 8.8 
(out of 10), there is reason to suspect that at least a handful of individuals entered the 
larger treatment outcome study for the financial incentives associated with participating.  
Therefore, it is unclear if all participants really made a concerted effort to try and quit 
smoking.  Indeed, there was a significant correlation between income level and smoking 
such that, as income level went up so did number of days abstinent.  While there are a 
number of factors besides motivation which may account for this difference (Gilman, 
Abrams, & Buka, 2003; Manfredi, Cho, Young, & Crittenden, 2007), future studies 
should apply more rigorous assessment of motivation to ensure that participants are truly 
ready to try and quit.   
On a related note, the smoking cessation treatment used in this current study 
yielded very low quit rates.  Research has suggested that a combination of a 
pharmacological agent and behavioral treatment produces the most favorable quitting 
outcome with quit rates ranging from 21-67%, depending upon treatment and abstinence 
assessment points used (Ingersoll & Cohen, 2005).  However, within this sample, over 
70% of participants lapsed within the first week and only about 10% of the sample 
remained abstinent at one month.  Research has shown that smokers with current elevated 
levels of depression tend to fare worse than nondepressed smokers on quitting (Rausch, 
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Nichinson, Lamke, & Matloff, 1990),  Moreover, consistent with the population used in 
this study, this effect has even been documented in smokers with fairly low subclinical 
levels of depression (Niaura, et al., 2001).  However, it is likely that elevated depressive 
symptoms are not enough to solely account for the poor outcome in this study.  As 
discussed above, it is possible that motivation could have played a role in these low 
relapse rates.  On a related note, there is some evidence to suggest that low income 
African Americans have lower quit rates compared to other populations (Fiore et al., 
1996; King, Polednak, Bendel, Vilsaint, & Nahata, 2004).  Finally, it is possible that part 
of the low quit rate could be attributable to the choice of NRT used in this study.  For 
convenience and its benign side effect profile, the Nicoderm CQ nicotine patch was the 
pharmacological aid employed in this treatment.  While the Nicotine patch provides a 
passive steady flow of nicotine throughout the day, it does not provide an immediate 
burst of nicotine to help during a craving.  Therefore, it is possible that another type of 
NRT used alone or in conjunction with the patch would have yielded better results 
(Foulds, Steinberg, & Williams, 2006).  
 The current study only assessed smoking abstinence for one month after the quit 
date.  Distress tolerance has been conceptualized to be an important component of early 
smoking lapse based on premise that the initial weeks of quitting smoking are 
characterized by uncomfortable withdrawal symptoms and a general elevation in stress 
associated with the quit process (Brown, Lejuez, Kahler, Strong, & Zvolensky, 2005).  
As such, those individuals who exhibit an inability to tolerate this discomfort are more 
vulnerable to give in to the immediate negative reinforcement provided by smoking.  
However, there is some available evidence to suggest that distress tolerance may also be 
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relevant to more long term smoking lapses and may not be specific to early lapses 
(Brandon et al., 2003; Stipelman et al., 2007).  Therefore, future studies need to include 
more long term follow-up to gain a more complete understanding of the role of distress 
tolerance across the quitting process. 
 One of the strengths of the current study was the use of multiple methods and 
multiple measures of the distress tolerance construct.  The majority of studies 
investigating the role of distress tolerance (or related constructs such as persistence or 
learned industriousness) in smoking have included only one method of assessment (e.g. 
behavioral tasks, self reports, etc...).  However, each type of measure has its own inherent 
set of advantages and limitations. As such, it will be important for future studies to 
include a range of distress tolerance measures in order to develop a more reliable and 
valid assessment battery for measuring this construct that can be compared across studies.  
For example, behavioral assessments are the most common measurement of distress 
tolerance and are an easy way to obtain objective information regarding one’s ability to 
tolerate discomfort.  However, behavioral tasks have the disadvantage of being 
influenced by other factors such as motivation or experiment demand characteristics 
(Meyer et al., 2001).  Self-report questionnaires are a cheap and efficient method for 
gathering data on large samples.  In addition, they are able to assess for emotional aspects 
of distress tolerance (e.g. depression, anxiety) that may be important to smoking lapse 
and can not be measured using experiential paradigms (Simons & Gaher, 2005).  On the 
other hand, self-report questionnaires measuring behaviors and/or internal states are 
subject to a number of weaknesses including possible lack of insight or understanding of 
the questions (Lucas & Baird, 2006) and response biases such as careless responding, 
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omissions, extremity bias and socially desirable responding (Paulhus, 1991).  Finally, this 
was one of the first studies which included a biological indicator of distress tolerance 
(salivary cortisol).  In order to gain a comprehensive understanding of distress tolerance it 
is important to elucidate the role that various physiological mechanisms play in 
regulating stress and discomfort.  However, one of the major disadvantages in collecting 
biological measures are the significant number of confounds that are difficult to control 
for and the sensitivity required to ensure a clean sample.  Despite these issues, it is 
important that future studies provide a more clear understanding of the role of the HPA 
axis, as well as other potentially important biological indices such as heart rate variability 
and blood pressure. 
Lastly, future studies are needed to develop a more integrative model of distress 
tolerance.  The lack of convergent validity found across presumed measures of distress 
tolerance suggests that it may not be a simple unitary construct.  Rather, it appears that 
distress tolerance can be conceptualized across a number of domains including physical, 
psychological, physiological, and emotional.  More work will need to be done to develop 
a clearer understanding of the distress tolerance construct and how it is related to 
smoking cessation both as a unique predictor and a moderator of other smoking related 
variables. 
Implications 
 Despite their limited generalizability, results from this study have potential 
implications for the conceptualization and treatment of cigarette smoking.  Specifically, 
these findings add to the growing body of literature suggesting that there are unique 
differences between those smokers who lapse back to smoking early compared to those 
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who are able to go on and sustain longer term quit attempts.  Although the distress 
tolerance literature is still in its early stages, as a more clear definition of the construct 
emerges it may make sense to provide smokers looking to quit with a distress tolerance 
paradigm to determine their potential risk for early smoking lapse.  
 Despite the early stages of this line of research, these findings have possible 
implications for the way in which cigarette smoking is treated.  By and large, current 
behavioral smoking cessation treatments have focused on a handful of components such 
as relapse prevention, support, and motivational interviewing (Fiore et al 2000).  While 
these strategies are certainly important aspects of treatment, the results from this study 
suggest that at least for some smokers, it may be advantageous to also include treatment 
elements aimed at increasing one’s distress tolerance.  Brown and colleagues (2005) have 
actually outlined such a treatment program that would include standard behavioral 
strategies in conjunction with exposure and acceptance based elements designed to 
increase the individual’s distress tolerance.  Specifically, the authors propose that prior to 
their quit date, smokers would engage in systematic and repeated periods of abstinence 
designed to help them habituate and develop coping skills to manage the unpleasant 
withdrawal symptoms associated with smoking cessation.  Secondly, the authors suggest 
that a distress tolerance treatment for smoking should also utilize acceptance based 
strategies which can improve cognitive flexibility and teach the individual to be willing 
to accept discomfort on the way to achieving their nonsmoking goal.  Consistent with 
Brown and colleagues (2005), research should be conducted to design and test novel 
smoking cessation treatment programs that address the issue of distress tolerance.   
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